{"gene":"SOX17","run_date":"2026-04-28T20:42:08","timeline":{"discoveries":[{"year":2007,"finding":"SOX17 physically interacts with TCF/LEF family members via its HMG box domain and with β-catenin, promoting proteasomal degradation of both β-catenin and TCF proteins via a glycogen synthase kinase 3β-independent mechanism, thereby repressing β-catenin/TCF transcriptional activity and inhibiting proliferation in colon carcinoma cells.","method":"Co-immunoprecipitation, gain- and loss-of-function experiments, proteasome inhibitor treatment, luciferase reporter assay, dose-response overexpression in SW480 cells","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (Co-IP, functional rescue, reporter assay, proteasome inhibitor) in a single rigorous study","pmids":["17875931"],"is_preprint":false},{"year":2009,"finding":"The crystal structure of the SOX17 HMG domain bound to DNA shows it bends DNA ~80° by targeting the minor groove, similar to SOX2, but presents an altered charge distribution at the Oct-factor interaction interface, predicting differential co-factor recruitment relative to SOX2.","method":"X-ray crystallography at 2.7 Å resolution; DNA-binding affinity measurements","journal":"Journal of molecular biology","confidence":"High","confidence_rationale":"Tier 1 — crystal structure with functional validation of DNA affinity","pmids":["19328208"],"is_preprint":false},{"year":2011,"finding":"SOX17 and SOX2 exhibit inverse heterodimerization preferences with OCT4 on canonical vs. compressed Sox/Oct DNA motifs; exchange of single amino acids at the OCT4 interaction interface converts SOX17 into a pluripotency reprogramming factor (SOX17EK) and abolishes SOX2 reprogramming activity (SOX2KE), demonstrating that the DNA-dependent Sox/Oct dimer configuration determines cell-fate outcome.","method":"Structure-based mutagenesis, somatic cell reprogramming assays, ESC overexpression, DNA-binding studies","journal":"Stem cells (Dayton, Ohio)","confidence":"High","confidence_rationale":"Tier 1 — mutagenesis combined with functional reprogramming assay and structural rationale, replicated concept in EMBO 2013","pmids":["21472822"],"is_preprint":false},{"year":2013,"finding":"SOX17 partners with OCT4 and binds a 'compressed' Sox/Oct motif that earmarks endodermal genes, in contrast to the canonical motif used by the OCT4-SOX2 complex in pluripotency; the compressed motif is required for proper endodermal gene expression in a differentiation assay.","method":"ChIP-seq, DNA motif analysis, endodermal differentiation reporter assay, point-mutant protein studies","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1-2 — genomic binding data combined with mutagenesis and functional differentiation assay","pmids":["23474895"],"is_preprint":false},{"year":2014,"finding":"SOX17 is the key transcriptional regulator of human primordial germ cell (hPGC) fate specification, whereas in mouse PGC specification this role is played by SOX2; BLIMP1 acts to repress somatic/endodermal genes during hPGCLC specification.","method":"hPGCLC specification from human pluripotent stem cells, loss-of-function (siRNA/knockout), gain-of-function, transcriptome analysis, cell surface marker characterization","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods, highly cited foundational study","pmids":["25543152"],"is_preprint":false},{"year":2013,"finding":"Endothelial-specific inactivation of Sox17 in mice causes loss of arterial identity and vascular remodeling defects; mechanistically, Sox17 acts downstream of canonical Wnt signaling and upstream of the Notch signaling system in arterial specification.","method":"Conditional endothelial knockout mice, epistasis experiments with Wnt and Notch pathway components, postnatal retina vascular analysis","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 — clean conditional KO with defined molecular epistasis (Wnt upstream, Notch downstream)","pmids":["24153254"],"is_preprint":false},{"year":2013,"finding":"SOX17 is expressed in haemogenic endothelium and regulates hematopoietic stem cell development through the Notch signalling pathway; Sox17 deletion abolishes haemogenic endothelial development in vivo and in the ESC differentiation model.","method":"Sox17-GFP reporter mice, ESC differentiation model, conditional knockout, Notch pathway analysis","journal":"Nature cell biology","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal approaches (reporter, KO, ESC model) in a single study","pmids":["23604320"],"is_preprint":false},{"year":2004,"finding":"SOX17 binds to two SOX-binding sites within the parietal endoderm-specific enhancer of the mouse laminin α1 (Lama1) gene and trans-activates transcription in a manner dependent on HMG box-mediated DNA binding, with synergistic cooperation between the two SOX sites and adjacent Sp1/Sp3 and NF-Y binding sites.","method":"Luciferase reporter assay, EMSA, mutational analysis, Northern blot, F9 cell differentiation model","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — in vitro DNA binding (EMSA) plus functional reporter assay with mutagenesis","pmids":["15220343"],"is_preprint":false},{"year":2006,"finding":"Sox17 controls both cell cycle exit and differentiation of oligodendrocyte progenitor cells (OPCs); siRNA-mediated knockdown increases OPC proliferation and decreases lineage progression, while overexpression enhances myelin gene expression and directly stimulates MBP gene promoter activity.","method":"siRNA knockdown, overexpression, FACS purification, promoter reporter assay, immunostaining","journal":"The Journal of neuroscience","confidence":"High","confidence_rationale":"Tier 2 — reciprocal gain/loss-of-function with promoter reporter and multiple cellular readouts","pmids":["16988043"],"is_preprint":false},{"year":2019,"finding":"HIF1α transcriptionally activates Sox17 expression during endotoxemia; Sox17 in turn upregulates Cyclin E1 to drive endothelial cell proliferation and regeneration after inflammatory vascular injury; genetic lineage tracing shows native endothelium is the primary source of repopulating endothelial cells.","method":"Endothelial-specific Sox17 deletion and overexpression, genetic lineage tracing, ChIP, CyclinE1 functional studies, endotoxemia mouse model","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 — conditional KO/OE with mechanism (HIF1α→Sox17→CyclinE1) supported by multiple orthogonal experiments","pmids":["31073164"],"is_preprint":false},{"year":2011,"finding":"Sox17 expression in adult hematopoietic stem cells (HSCs) and transiently reconstituting progenitors is sufficient to confer fetal HSC characteristics including increased self-renewal potential and fetal surface marker expression; long-term ectopic Sox17 expression eventually leads to leukemogenesis.","method":"Retroviral Sox17 overexpression in adult HSCs, bone marrow transplantation/reconstitution assay, gene expression profiling","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 — gain-of-function in primary HSCs with in vivo reconstitution readout","pmids":["21828271"],"is_preprint":false},{"year":2014,"finding":"Notch signaling suppresses Sox17 expression predominantly at the post-transcriptional level in stalk cells; Sox17 promotes endothelial tip cell behavior by destabilizing junctions and rearranging cytoskeletal structure, and upregulates tip-cell-enriched genes including VEGFR2; endothelial Sox17 deletion rescues hyperbranching caused by Notch inhibition.","method":"Endothelial-specific Sox17 deletion/overexpression mice, Notch intracellular domain overexpression, Dll4 blockade, retinal angiogenesis analysis, gene expression studies","journal":"Circulation research","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis between Notch and Sox17 validated with multiple in vivo and in vitro approaches","pmids":["24755984"],"is_preprint":false},{"year":2019,"finding":"Sox17 regulates blood-brain barrier (BBB) permeability; endothelial-specific Sox17 inactivation increases brain microvascular permeability; mechanistically, Sox17 acts as a positive inducer of Wnt/β-catenin signaling (members of the pathway are downstream targets), and inhibition of the β-catenin destruction complex rescues the permeability defect caused by Sox17 loss.","method":"Endothelial-specific Sox17 knockout mice, RNA-seq of brain endothelial cells, β-catenin stabilization rescue experiments, reporter mice","journal":"Circulation research","confidence":"High","confidence_rationale":"Tier 2 — conditional KO with RNA-seq and genetic rescue experiments","pmids":["30591003"],"is_preprint":false},{"year":2020,"finding":"In Xenopus, Sox17 and β-catenin co-occupy hundreds of Wnt-responsive enhancers in the endoderm; on some enhancers Sox17 and β-catenin synergistically activate transcription independently of TCF factors, while on others Sox17 represses β-catenin/TCF-mediated transcription; Sox17 acts as a tissue-specific modifier of Wnt responses to specify endoderm while repressing mesectoderm fates.","method":"ChIP-seq, ATAC-seq, epistasis experiments, luciferase reporter assays, Xenopus gastrula genomic approaches","journal":"eLife","confidence":"High","confidence_rationale":"Tier 1-2 — genome-wide binding data plus epistasis and reporter assays with orthogonal methods","pmids":["32894225"],"is_preprint":false},{"year":2022,"finding":"SOX17 physically interacts with PAX8 in ovarian cancer cells; the two transcription factors co-occupy overlapping genomic regions and regulate a common set of downstream genes including those involved in cell cycle and tissue morphogenesis; together they suppress SERPINE1 expression to promote secretion of pro-angiogenic factors.","method":"PAX8 protein complex purification (pulldown), Co-IP, ChIP-seq, siRNA depletion, in vitro tube formation assay, mouse xenograft model","journal":"Science signaling","confidence":"High","confidence_rationale":"Tier 2 — reciprocal protein purification + genomic co-occupancy + functional assays in two cell contexts","pmids":["35380877"],"is_preprint":false},{"year":2022,"finding":"Sox17 deficiency in pulmonary endothelial cells activates HGF/c-Met signaling; Sox17-deficient lung endothelial cells upregulate HGF (a c-Met ligand), and pharmacological inhibition of HGF/c-Met attenuates PAH features in both preventive and therapeutic settings in mouse models.","method":"EC-specific Sox17 deletion mice, transcriptomic profiling, pharmacological HGF/c-Met inhibition, hypoxia model of PAH","journal":"Circulation research","confidence":"High","confidence_rationale":"Tier 2 — conditional KO with transcriptomic mechanism and pharmacological rescue","pmids":["36205124"],"is_preprint":false},{"year":2021,"finding":"SOX17 directly activates CDX2 expression in hemogenic endothelium (HE), which upregulates HOXA cluster genes; SOX17 also activates Notch signaling and is required for specification of HE with lympho-myeloid potential and arterial HE identity (DLL4+CXCR4+ phenotype).","method":"SOX17-knockout and SOX17-inducible hPSCs, molecular profiling, ChIP, transcriptomic analysis","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 — KO and inducible OE in human PSCs with direct target (CDX2) identified by ChIP","pmids":["33596423"],"is_preprint":false},{"year":2018,"finding":"SOX17 trans-suppresses β-catenin expression by directly binding to the β-catenin promoter, thereby inhibiting Wnt/β-catenin pathway activity and restraining proliferation in cervical cancer cells.","method":"Luciferase reporter assay, quantitative ChIP (qChIP), TOP/FOP-Flash assay, Western blot, colony formation assay, nude mouse tumor model","journal":"Cell death & disease","confidence":"High","confidence_rationale":"Tier 1-2 — direct promoter binding confirmed by ChIP plus functional reporter and mutagenesis","pmids":["29970906"],"is_preprint":false},{"year":2012,"finding":"Sox17 in tumor endothelial cells promotes endothelial sprouting and upregulates VEGFR2 expression in a cell-intrinsic manner; it also increases tumor-associated CD11b+Gr-1+ myeloid cell recruitment; Sox17 deletion in tumor ECs normalizes tumor vessels and reduces tumor growth.","method":"Sox17 conditional deletion and overexpression in endothelial cells, tumor transplantation models, VEGFR2 expression analysis","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 — conditional gain/loss-of-function with defined molecular (VEGFR2) and cellular phenotypic readouts","pmids":["23241958"],"is_preprint":false},{"year":2014,"finding":"Forced expression of Sox17 in mouse ESC-derived AGM CD45low c-Kit high intra-aortic cluster cells maintains their cluster-forming and HSC identity in vitro and long-term reconstitution activity in vivo; shutdown of Sox17 results in immediate hematopoietic differentiation, indicating Sox17 controls the HSC fate decision between self-renewal and differentiation.","method":"Retroviral Sox17 overexpression with inducible shutdown, stromal co-culture cluster assay, long-term bone marrow reconstitution","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 — inducible gain/loss-of-function with in vivo reconstitution readout","pmids":["24662049"],"is_preprint":false},{"year":2014,"finding":"SOX17 is required for cardiac mesoderm/cardiomyocyte differentiation in mouse ESCs; downstream targets Hhex and Cer1 are indispensable components of this pathway—SOX17 directly activates Cer1 transcription (demonstrated by ChIP and luciferase reporter), Hhex is required for Cer1 expression, and forced Cer1 expression rescues cardiac differentiation in Hhex-deficient cells.","method":"RNAi, genome-wide profiling, ChIP, luciferase reporter assays, rescue experiments in ESC differentiation model","journal":"Stem cells (Dayton, Ohio)","confidence":"High","confidence_rationale":"Tier 1-2 — direct target identification by ChIP plus epistasis and functional rescue","pmids":["24585688"],"is_preprint":false},{"year":2013,"finding":"Sox17 acts in autoregulatory and feedforward gene regulatory network motifs during ESC-to-XEN cell conversion; forced Sox17 expression in ESCs drives them toward extraembryonic endoderm (XEN) identity with distinct intermediate states.","method":"Forced Sox17 expression in ESCs, embryo injection functional test, transcriptomic analysis of intermediate states","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 — single study with functional conversion and network analysis but limited biochemical mechanistic detail","pmids":["25373912"],"is_preprint":false},{"year":2019,"finding":"In endometrial cancer cells, SOX17 binds to the MAML3 promoter and downregulates MAML3 transcription; MAML3 is a co-activator of β-catenin-mediated transcription and requires its C-terminal region for SOX17 binding; the SOX17-MAML3 interaction was confirmed by Co-IP in cell nuclei.","method":"Co-IP, luciferase reporter assay (MAML3 promoter binding), Western blot, in vivo xenograft model","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2-3 — Co-IP and reporter assay, single study","pmids":["27738313"],"is_preprint":false},{"year":2009,"finding":"Sox17 overexpression in gastric cancer cells suppresses Wnt/β-catenin transcriptional activity and colony formation; Sox17 is induced by Wnt activation in early gastric tumors but silenced by DNA methylation during malignant progression; transgenic Sox17 expression suppresses dysplastic tumor development in K19-Wnt1/C2mE mice.","method":"Sox17 transfection, luciferase reporter assay, demethylating agent treatment, transgenic mice","journal":"Gastroenterology","confidence":"Medium","confidence_rationale":"Tier 2 — functional reporter + in vivo transgenic model, single lab","pmids":["19549530"],"is_preprint":false},{"year":2023,"finding":"PAH risk alleles upstream of SOX17 reduce endothelial SOX17 expression through differential binding of transcription factors HOXA5 and ROR-α (confirmed by EMSA and antibody-EMSA); SOX17 silencing in hPAECs alters extracellular matrix regulation, increases apoptosis, proliferation, and disrupts barrier function; SOX17 enhancer knockout in mice exacerbates hypoxia-induced pulmonary hypertension.","method":"CRISPR enhancer deletion, siRNA, EMSA, RNA-seq, in vivo pulmonary hypertension mouse model","journal":"Circulation","confidence":"High","confidence_rationale":"Tier 1-2 — EMSA-confirmed TF binding to disease variants plus multiple functional readouts in vivo and in vitro","pmids":["37066790"],"is_preprint":false},{"year":2023,"finding":"E2F1 signaling mediates SOX17 deficiency-induced endothelial dysfunction and pulmonary hypertension; loss of endothelial Sox17 upregulates E2F1-driven cell cycle programming; pharmacological E2F1 inhibition in Sox17 EC-deficient mice attenuates pulmonary hypertension.","method":"Tie2Cre-mediated Sox17 knockdown, EC-specific Sox17 deletion, scRNA-seq, RNA-seq, luciferase assay, pharmacological E2F1 inhibition in vivo","journal":"Hypertension (Dallas, Tex. : 1979)","confidence":"High","confidence_rationale":"Tier 2 — conditional KO with pharmacological rescue identifying E2F1 as downstream mediator","pmids":["37066790","37737027"],"is_preprint":false},{"year":2023,"finding":"SOX17 deficiency increases HIF2α levels in pulmonary endothelial cells; increased SOX17 promotes oxidative phosphorylation and mitochondrial function partly counteracted by HIF2α overexpression; the pathological estrogen metabolite 16α-hydroxyestrone represses SOX17 promoter activity to exacerbate pulmonary hypertension.","method":"Seahorse metabolic assay, promoter luciferase assay, Tie2-Sox17 KO and Tg mice, chronic hypoxia model, untargeted proteomics","journal":"American journal of respiratory and critical care medicine","confidence":"High","confidence_rationale":"Tier 1-2 — mechanistic promoter assay + metabolic assays + in vivo genetic models","pmids":["36913491"],"is_preprint":false},{"year":2024,"finding":"SOX17 suppresses the ability of colorectal tumor cells to sense and respond to IFNγ (preventing anti-tumour T cell responses) and drives differentiation toward LGR5- immune-evasive cells with lower MHC-I expression by engaging a fetal intestinal programme; SOX17 loss in AKP organoid tumors markedly reduces in vivo persistence and elicits IFNγ-producing CD8+ T cell infiltrates.","method":"SOX17-null organoid transplantation into mouse colons, transcriptomic and chromatin analyses, endogenous Apc-null adenoma model, IFNγ response assays","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal in vivo and molecular approaches in a single rigorous study","pmids":["38418875"],"is_preprint":false},{"year":2017,"finding":"SOX17 regulates the differentiation and maintenance of the biliary/cholangiocyte phenotype; SOX17 knockdown in differentiated normal human cholangiocytes downregulates biliary markers and promotes Wnt-dependent proliferation; in CCA cells, SOX17 overexpression inhibits Wnt/β-catenin-dependent proliferation, migration, anchorage-independent growth, and restores primary cilium length; Wnt3a decreases SOX17 expression via a DNMT-dependent mechanism.","method":"Lentiviral SOX17 overexpression/knockdown, iPSC-to-cholangiocyte differentiation, xenograft model, gene expression profiling, DNA methylation profiling","journal":"Journal of hepatology","confidence":"High","confidence_rationale":"Tier 2 — reciprocal gain/loss-of-function with multiple mechanistic readouts and in vivo validation","pmids":["28237397"],"is_preprint":false},{"year":2019,"finding":"SOX17 acts as a transcriptional repressor of NRF2; ChIP and promoter reporter analyses demonstrated direct SOX17 binding to the NRF2 promoter and suppression of its activity, providing a mechanism for chemoradiotherapy sensitization in esophageal squamous cell carcinoma.","method":"ChIP-qPCR, promoter luciferase reporter assay, SOX17 overexpression, xenograft model","journal":"Journal of biomedical science","confidence":"Medium","confidence_rationale":"Tier 1-2 — direct promoter binding by ChIP plus reporter assay, single lab","pmids":["36310172"],"is_preprint":false},{"year":2019,"finding":"SOX17 transcriptionally downregulates DNA repair and damage response genes (BRCA1, BRCA2, RAD51, KU80, DNAPK, p21, SIRT1, NFAT5, REV3L) in radio-resistant esophageal cancer cells, sensitizing them to chemoradiation; demonstrated by luciferase and ChIP-qPCR assays.","method":"Luciferase reporter assay, ChIP-qPCR, SOX17 overexpression, xenograft model, clonogenic survival assay","journal":"Journal of biomedical science","confidence":"Medium","confidence_rationale":"Tier 2 — direct transcriptional target identification by ChIP plus functional sensitization, single lab","pmids":["30777052"],"is_preprint":false},{"year":2017,"finding":"SOX17 acts as a transcriptional suppressor of MRP3 (ABCC3) in cholangiocarcinoma cells; SOX17 expression prevents SOX2/SOX9-induced electrophoretic mobility shift of the ABCC3 promoter; this MRP3 downregulation reduces drug efflux and selectively sensitizes CCA cells to SN-38, 5-FU and mitoxantrone.","method":"TaqMan array resistome analysis, promoter reporter assay, EMSA, immunofluorescence, SOX17 adenoviral transduction, xenograft mouse model","journal":"Hepatology (Baltimore, Md.)","confidence":"High","confidence_rationale":"Tier 1-2 — EMSA plus reporter plus in vivo rescue, multiple orthogonal methods","pmids":["31863486"],"is_preprint":false},{"year":2021,"finding":"GATA3 or GATA2 (immediate BMP effectors) combined with SOX17 and TFAP2C are required to generate human PGCLCs; GATA3/GATA2 knockouts dose-dependently impair BMP-induced hPGCLC specification while remaining unaffected by SOX17, TFAP2C, or BLIMP1 knockouts, placing GATA3/2 upstream of SOX17 in the germ-cell specification transcription factor circuitry.","method":"TF overexpression, CRISPR knockout, hPGCLC specification assay, xenogeneic reconstituted ovary culture","journal":"Life science alliance","confidence":"High","confidence_rationale":"Tier 2 — epistasis via CRISPR KO combined with reconstitution assay","pmids":["33608411"],"is_preprint":false},{"year":2019,"finding":"Sox17 deletion from endocardium precursor cells impairs endocardium proliferation and behavior, and in a non-cell-autonomous manner reduces cardiomyocyte proliferation, ventricular trabeculation and myocardium thickening, associated with downregulation of NOTCH signaling in the mutant.","method":"Mesoderm-specific Sox17 conditional deletion, cardiac phenotypic analysis, Notch target gene expression","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 — conditional KO with defined Notch pathway readout, single lab","pmids":["31420575"],"is_preprint":false},{"year":2014,"finding":"Sox17 regulates insulin secretion in pancreatic β cells; Sox17 pancreas-specific deletion results in elevated islet proinsulin content, abnormal proinsulin trafficking, dilated secretory organelles, and susceptibility to hyperglycemia; Sox17 overexpression broadly regulates secretory network gene expression and can reverse insulin secretory defects in MODY4 animals.","method":"Pancreas-specific Sox17 conditional knockout, Ins2-rtTA overexpression, transcriptome analysis (24-hour SOX17 pulse), electron microscopy of organelles","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 — conditional KO + inducible OE with cellular and transcriptomic readouts, single lab","pmids":["25144761"],"is_preprint":false},{"year":2014,"finding":"Sox17 regulates liver lipid metabolism and adaptation to fasting through modulation of PPARα-driven transcription; a missense mutation in the HMG domain of Sox17 impairs PPARα-dependent fatty acid oxidation gene induction during fasting; fenofibrate (PPARα agonist) partially rescues the fasting phenotype.","method":"Forward genetic screen, ENU mutagenesis, transcriptomic analysis, metabolic phenotyping, fenofibrate rescue in Sox17 mutant mice","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 — in vivo HMG-domain missense mutant with transcriptomic and pharmacological rescue","pmids":["25141153"],"is_preprint":false},{"year":2024,"finding":"The deubiquitinase UCHL1 interacts with Sox17 (identified by IP-mass spectrometry) and stabilizes the Sox17 protein; UCHL1 conditional knockout reduces Sox17 levels, impairs angiogenesis and blood-spinal cord barrier repair after spinal cord injury; rescue experiments confirm the UCHL1-Sox17 axis is required for endothelial regeneration.","method":"IP-mass spectrometry, UCHL1 conditional knockout mice, Sox17 knockdown/overexpression, rescue experiments, in vitro endothelial tube formation, in vivo SCI model","journal":"Cellular and molecular life sciences","confidence":"Medium","confidence_rationale":"Tier 2-3 — IP-MS identification of interaction plus conditional KO rescue, single lab","pmids":["38478109"],"is_preprint":false},{"year":2023,"finding":"SOX17 overexpression promotes exosome-mediated autocrine release of miR-224-5p and miR-361-3p in pulmonary artery endothelial cells; these miRNAs are internalized by injured HPAECs and repress NR4A3 and PCSK9, improving endothelial function and attenuating pulmonary hypertension in SU5416/hypoxia mice.","method":"Exosome isolation and characterization, miRNA profiling, gain/loss-of-function in HPAECs and mice, luciferase target validation, in vivo SOX17 overexpression","journal":"Advanced science","confidence":"Medium","confidence_rationale":"Tier 2-3 — mechanistic exosome-miRNA pathway identified with in vivo model, single lab","pmids":["36919784"],"is_preprint":false},{"year":2013,"finding":"SOX17 Sox17 promotes oligodendrocyte lineage survival under demyelinating conditions; Sox17 transgenic overexpression increases Gli2 protein levels in white matter, indicating Sox17 promotes oligodendrocyte generation through Hedgehog signaling, and prevents injury-induced TCF7L2/TCF4+ cell expansion and apoptosis by maintaining Gli2 and Bcl-2 expression.","method":"CNP-Sox17 transgenic mice, lysolecithin demyelination model, western blot, immunostaining","journal":"The Journal of neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 — transgenic OE in demyelination model with Hedgehog pathway readout, single lab","pmids":["23884956"],"is_preprint":false},{"year":2017,"finding":"SOX17 regulates fibroblast lineage conversion to endothelial cells and erythroblasts via intermediate CD34+ progenitors; endothelial conversion requires SOX17 upregulation, while SOX17 suppression directs cells toward erythroid fate; implanted cells form functional microvessels in NOD-SCID mice.","method":"Fibroblast reprogramming, CD34+ sorting, SOX17 overexpression/suppression, lineage-specific differentiation assays, mouse myocardial infarction model","journal":"Circulation","confidence":"Medium","confidence_rationale":"Tier 2 — gain/loss-of-function identifying SOX17 as a bifurcation switch, single lab","pmids":["28381471"],"is_preprint":false},{"year":2016,"finding":"Biliatresone causes a rapid decrease in glutathione and SOX17 levels in mouse cholangiocytes; GSH decrease is necessary and sufficient for biliatresone effects; Sox17 knockdown in cholangiocyte spheroids mimics biliatresone-induced disruption of apical polarity and monolayer integrity.","method":"3D cholangiocyte spheroid culture, neonatal bile duct explants, Sox17 siRNA knockdown, rhodamine efflux permeability assay","journal":"Hepatology (Baltimore, Md.)","confidence":"Medium","confidence_rationale":"Tier 2 — knockdown phenocopying toxin in 3D culture plus explant model, single lab","pmids":["27081925"],"is_preprint":false},{"year":2009,"finding":"In Xenopus, Sox17 acts as an immediate-early target of VegT in vegetal blastomeres: VegT activates Sox17α at the MBT independently of Nodal; thereafter, Sox17α prevents mesodermal gene expression (Xbra, MyoD) in response to Nodal signals while permitting endodermal gene expression, thereby establishing the endodermal domain.","method":"Inhibitor injection (VegT/Nodal MOs), animal cap explants, cycloheximide treatment, Nodal antagonist, gene expression analysis","journal":"Developmental biology","confidence":"High","confidence_rationale":"Tier 2 — epistasis experiments with multiple pathway components in Xenopus (ortholog)","pmids":["11518513"],"is_preprint":false},{"year":2009,"finding":"Oct4 switches binding from the Sox2 promoter to the Sox17 promoter upon BMP2-induced upregulation, turning off the pluripotency Oct4-Sox2 loop and activating Sox17-positive endodermal cells that produce cardiogenic paracrine signals (Wnt, BMP2).","method":"Oct4 overexpression and BMP2 treatment in human ESCs and iPSCs, ChIP (Oct4 on Sox17 promoter), promoter activity assay","journal":"The Journal of cell biology","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP evidence for Oct4 promoter switch plus functional differentiation assay, single lab","pmids":["19736317"],"is_preprint":false},{"year":2010,"finding":"SOX17 promoter methylation silences its expression in HCC; restoration of SOX17 inhibits HepG2 colony formation and β-catenin/TCF-dependent transcription in a manner dependent on the HMG box; HCC with methylated SOX17 is associated with nuclear β-catenin accumulation.","method":"MSP, 5-aza-2'-deoxycytidine re-expression, luciferase reporter assay, colony formation assay, IHC","journal":"Epigenetics","confidence":"Medium","confidence_rationale":"Tier 2-3 — reporter assay + epigenetic re-expression + HMG box requirement, single lab","pmids":["20716954"],"is_preprint":false},{"year":2021,"finding":"In seminoma-like cells, SOX17 binds canonical (SOX2/OCT4), compressed (SOX17/OCT4), and non-composite SOX motifs; it regulates TFAP2C, PRDM1, and PRDM14 to maintain latent pluripotency and suppress somatic differentiation; SOX17 deletion reduces OCT4 protein and alkaline phosphatase activity, showing SOX17 functionally replaces SOX2 to maintain the pluripotency cluster in seminomas.","method":"ChIP-seq, CRISPR-mediated SOX17 deletion, alkaline phosphatase activity assay, Western blot","journal":"International journal of cancer","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP-seq plus CRISPR KO with functional readouts, single lab","pmids":["31583686"],"is_preprint":false}],"current_model":"SOX17 is an HMG-box transcription factor that: (1) bends DNA ~80° and forms alternative heterodimers with OCT4 on compressed vs. canonical Sox/Oct motifs to drive endoderm vs. pluripotency gene programs; (2) represses Wnt/β-catenin signaling by promoting proteasomal degradation of β-catenin and TCF, directly binding the β-catenin promoter, and physically interacting with TCF/LEF and co-factors such as MAML3; (3) functions downstream of canonical Wnt and upstream of Notch signaling to specify arterial identity and regulate vascular sprouting, BBB integrity, and pulmonary vascular homeostasis; (4) acts as a key specifier of human primordial germ cell fate, definitive endoderm identity, oligodendrocyte differentiation, and haemogenic endothelium; (5) is regulated post-translationally by deubiquitinase UCHL1-mediated stabilization, and transcriptionally by promoter methylation, HIF1α, and estrogen metabolites; and (6) controls downstream targets including Cyclin E1 (endothelial regeneration), VEGFR2, CDX2/HOXA (hematopoiesis), NRF2, MRP3, and secretory network genes (insulin trafficking), with loss-of-function linked to pulmonary arterial hypertension via HGF/c-Met and E2F1 signaling."},"narrative":{"teleology":[{"year":2004,"claim":"Establishing that SOX17 functions as a sequence-specific transcriptional activator through its HMG box answered the basic question of how SOX17 engages endodermal target genes, using the Lama1 enhancer as a paradigm.","evidence":"EMSA, luciferase reporter, and mutational analysis in F9 parietal endoderm cells","pmids":["15220343"],"confidence":"High","gaps":["Limited to a single target gene enhancer","Genome-wide binding landscape unknown at this stage"]},{"year":2006,"claim":"Demonstrating that SOX17 controls both cell cycle exit and differentiation of oligodendrocyte progenitors revealed an unexpected non-endodermal role and showed SOX17 couples proliferation arrest to lineage progression.","evidence":"Reciprocal gain/loss-of-function in FACS-purified OPCs with MBP promoter reporter","pmids":["16988043"],"confidence":"High","gaps":["Direct transcriptional targets in OPCs beyond MBP not identified","Mechanism linking SOX17 to cell cycle exit unresolved"]},{"year":2007,"claim":"Revealing that SOX17 physically interacts with TCF/LEF and β-catenin and promotes their proteasomal degradation established SOX17 as a direct antagonist of canonical Wnt signaling through a GSK3β-independent mechanism.","evidence":"Co-IP, proteasome inhibitor rescue, luciferase reporter in SW480 colon carcinoma cells","pmids":["17875931"],"confidence":"High","gaps":["E3 ubiquitin ligase mediating β-catenin/TCF degradation not identified","Whether this degradation mechanism operates in non-cancer contexts unknown"]},{"year":2009,"claim":"The crystal structure of the SOX17 HMG domain on DNA showed that despite conserved minor-groove bending (~80°), an altered charge distribution at the co-factor interface predicts differential partner recruitment relative to SOX2, providing a structural basis for lineage-specific activity.","evidence":"X-ray crystallography at 2.7 Å with DNA-binding affinity measurements","pmids":["19328208"],"confidence":"High","gaps":["No co-crystal with OCT4 obtained","Structural basis of compressed vs. canonical motif selectivity not resolved"]},{"year":2009,"claim":"Xenopus studies and gastric cancer epigenetic analyses together established that SOX17 is an immediate-early endoderm specification factor (activated by VegT independently of Nodal) and that its promoter is silenced by DNA methylation in GI tumors, linking developmental function to tumor suppression.","evidence":"Xenopus animal cap epistasis with cycloheximide/Nodal antagonists; MSP/demethylation plus transgenic mice in gastric cancer","pmids":["11518513","19549530"],"confidence":"High","gaps":["Methyltransferases responsible for SOX17 silencing not identified","Whether Nodal-independent activation is conserved in mammals unclear"]},{"year":2011,"claim":"Structure-guided swap of single residues at the OCT4 interface (SOX17EK) converted SOX17 into a pluripotency reprogramming factor, proving that the DNA-dependent Sox/Oct dimer configuration—not the overall protein—dictates cell-fate outcome between endoderm and pluripotency.","evidence":"Mutagenesis, somatic cell reprogramming assays, ESC overexpression","pmids":["21472822"],"confidence":"High","gaps":["Downstream gene regulatory networks controlled by each dimer configuration not fully mapped","Whether compressed motif preference is hardwired or chromatin-dependent unknown"]},{"year":2011,"claim":"Ectopic SOX17 in adult HSCs conferred fetal-like self-renewal properties and eventually caused leukemia, establishing SOX17 as a master regulator of the fetal-to-adult HSC transition.","evidence":"Retroviral Sox17 overexpression in adult HSCs with serial bone marrow transplantation","pmids":["21828271"],"confidence":"High","gaps":["Direct transcriptional targets mediating fetal HSC identity not identified","Mechanism of leukemogenic transformation unresolved"]},{"year":2013,"claim":"Endothelial-specific Sox17 deletion and ChIP-seq studies established that SOX17 sits in a Wnt→SOX17→Notch epistatic hierarchy to specify arterial identity and regulate haemogenic endothelium, integrating its roles in vascular and hematopoietic development.","evidence":"Conditional EC knockout mice with Wnt/Notch epistasis; Sox17-GFP reporter in haemogenic endothelium; ChIP-seq identifying compressed Sox/Oct motifs at endodermal genes","pmids":["24153254","23604320","23474895"],"confidence":"High","gaps":["How SOX17 activates Notch ligand transcription mechanistically unclear","Relative contributions of Wnt-dependent vs. Wnt-independent SOX17 activation in vivo not dissected"]},{"year":2014,"claim":"Identification of SOX17 as the key transcription factor for human primordial germ cell specification—replacing the role of SOX2 in mouse—established a fundamental species-specific difference in germ cell biology.","evidence":"hPGCLC specification from hPSCs with siRNA/knockout, gain-of-function, transcriptome analysis","pmids":["25543152"],"confidence":"High","gaps":["Direct SOX17 targets in early hPGCs not comprehensively mapped","Mechanism by which SOX17 supersedes SOX2 function in humans not fully elucidated"]},{"year":2014,"claim":"Multiple 2014 studies clarified SOX17's downstream targets in distinct lineages: Cer1 in cardiac mesoderm, secretory network genes in pancreatic β cells, and VEGFR2 in tip cells, revealing that SOX17 controls tissue-specific gene programs rather than a single universal target set.","evidence":"ChIP/reporter for Cer1 in ESC cardiac differentiation; pancreas-specific KO with EM; EC-specific KO/OE retinal angiogenesis with Notch epistasis","pmids":["24585688","25144761","24755984"],"confidence":"High","gaps":["Cofactors that confer tissue-specific target selectivity largely unknown","Whether SOX17 directly binds VEGFR2 regulatory elements not confirmed by ChIP"]},{"year":2018,"claim":"Demonstrating that SOX17 directly binds the β-catenin promoter to transcriptionally repress β-catenin expression added a second mechanism—transcriptional repression—to the previously known post-translational degradation route for Wnt pathway antagonism.","evidence":"ChIP-qPCR on β-catenin promoter, TOP/FOP-Flash reporter, colony formation in cervical cancer cells","pmids":["29970906"],"confidence":"High","gaps":["Whether both mechanisms (degradation + transcriptional repression) operate simultaneously in the same cell type not tested"]},{"year":2019,"claim":"The HIF1α→SOX17→Cyclin E1 axis was identified as the mechanism for endothelial regeneration after inflammatory injury, resolving how native endothelium self-repairs and placing SOX17 as a proliferation driver in the vascular context.","evidence":"Endothelial-specific Sox17 deletion/OE, genetic lineage tracing, ChIP, endotoxemia model","pmids":["31073164"],"confidence":"High","gaps":["Whether this regenerative pathway operates in chronic vascular injury models unknown","Additional HIF1α-independent SOX17 activators not excluded"]},{"year":2019,"claim":"SOX17 was shown to maintain blood–brain barrier integrity; its loss increased brain microvascular permeability, and β-catenin stabilization rescued the defect, revealing that SOX17 positively reinforces Wnt/β-catenin signaling specifically in brain endothelium—contrasting with its Wnt-antagonist role in other contexts.","evidence":"Endothelial-specific Sox17 KO mice, RNA-seq, β-catenin destruction complex inhibitor rescue","pmids":["30591003"],"confidence":"High","gaps":["Mechanism by which SOX17 activates rather than represses Wnt pathway in brain EC not resolved","Whether BBB defect is developmental or maintenance-related not fully distinguished"]},{"year":2020,"claim":"Genome-wide co-occupancy of SOX17 and β-catenin on Wnt-responsive enhancers in Xenopus endoderm, with locus-dependent synergistic or antagonistic effects, resolved the paradox of SOX17 as both Wnt activator and repressor by showing it acts as a tissue-specific modifier of Wnt target selection.","evidence":"ChIP-seq, ATAC-seq, epistasis experiments, reporter assays in Xenopus gastrula","pmids":["32894225"],"confidence":"High","gaps":["Chromatin features or cofactors that determine synergy vs. antagonism at individual enhancers not identified","Whether this locus-specific logic is conserved in mammalian endoderm unclear"]},{"year":2021,"claim":"Placing GATA3/GATA2 upstream of SOX17 and identifying CDX2/HOXA as direct downstream targets in hemogenic endothelium completed the transcription factor hierarchy for human PGC and hematopoietic specification involving SOX17.","evidence":"CRISPR KO epistasis in hPGCLC assay; SOX17-KO/inducible hPSCs with ChIP for CDX2","pmids":["33608411","33596423"],"confidence":"High","gaps":["Full enhancer-level wiring connecting GATA→SOX17→CDX2 not mapped","Whether SOX17 requirement is dose-dependent or switch-like not tested"]},{"year":2022,"claim":"SOX17 was found to physically interact with PAX8 and co-regulate angiogenic and cell-cycle genes in ovarian cancer, identifying a non-canonical partner outside the SOX/OCT paradigm.","evidence":"Reciprocal pulldown, Co-IP, ChIP-seq co-occupancy, siRNA, tube formation assay, xenograft","pmids":["35380877"],"confidence":"High","gaps":["Structural basis of SOX17-PAX8 interaction unknown","Whether this complex operates outside ovarian cancer cells not tested"]},{"year":2022,"claim":"Endothelial Sox17 deficiency was linked to pulmonary arterial hypertension through de-repression of HGF/c-Met signaling, with pharmacological c-Met inhibition rescuing PAH, providing a therapeutic target downstream of SOX17 loss.","evidence":"EC-specific Sox17 deletion, transcriptomics, HGF/c-Met inhibitor rescue in hypoxia PAH model","pmids":["36205124"],"confidence":"High","gaps":["Whether SOX17 directly represses HGF transcription not demonstrated by ChIP","Applicability to human PAH patient-derived cells not shown"]},{"year":2023,"claim":"Common PAH risk variants were shown to reduce SOX17 expression via differential transcription factor binding (HOXA5, ROR-α) at an upstream enhancer, and E2F1 was identified as a key downstream effector of SOX17 loss in pulmonary hypertension, providing a genetic-to-mechanistic link for disease.","evidence":"EMSA, enhancer CRISPR KO, scRNA-seq, pharmacological E2F1 inhibition in Sox17-deficient mice","pmids":["37066790","37737027"],"confidence":"High","gaps":["Whether enhancer variants fully account for PAH penetrance unclear","Additional transcription factors binding the risk enhancer may exist"]},{"year":2024,"claim":"SOX17 was identified as a driver of immune evasion in colorectal cancer by suppressing IFNγ responsiveness and MHC-I expression through engagement of a fetal intestinal program, reframing SOX17 from a tumor suppressor to a context-dependent oncogenic factor.","evidence":"SOX17-null organoid transplantation, chromatin/transcriptomic analysis, CD8+ T cell infiltrate quantification","pmids":["38418875"],"confidence":"High","gaps":["Whether SOX17-driven immune evasion operates in other tumor types unknown","Direct chromatin targets mediating IFNγ pathway suppression not fully resolved"]},{"year":2024,"claim":"UCHL1 was identified as a deubiquitinase that stabilizes SOX17 protein, establishing the first post-translational regulatory mechanism for SOX17 turnover.","evidence":"IP-mass spectrometry, UCHL1 conditional KO mice, rescue experiments in spinal cord injury model","pmids":["38478109"],"confidence":"Medium","gaps":["E3 ligase that ubiquitinates SOX17 not identified","Ubiquitination sites on SOX17 not mapped","Whether UCHL1-SOX17 axis operates in endoderm or hematopoietic contexts untested"]},{"year":null,"claim":"Key unresolved questions include: the structural basis of the SOX17–OCT4 complex on compressed DNA motifs; the cofactors and chromatin features determining locus-specific Wnt synergy vs. antagonism; the E3 ligase(s) targeting SOX17 for ubiquitin-dependent degradation; and whether SOX17's context-dependent tumor-suppressive vs. immune-evasive roles can be therapeutically dissected.","evidence":"","pmids":[],"confidence":"High","gaps":["No SOX17–OCT4 co-crystal structure on compressed motif","E3 ligase for SOX17 ubiquitination unknown","Therapeutic window between endothelial protective and tumor immune-evasive functions not explored"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[1,2,3,7,13]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,7,8,9,17,29,30]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0,13,17]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[1,3,7,14,22,44]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,5,12,13,17,23]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[7,8,9,29,30]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[4,5,6,16,32,41]}],"complexes":[],"partners":["OCT4","TCF/LEF","CTNNB1","PAX8","MAML3","UCHL1","HIF1A"],"other_free_text":[]},"mechanistic_narrative":"SOX17 is an HMG-box transcription factor that specifies endodermal, vascular, hematopoietic, and germ cell fates by forming context-dependent transcriptional complexes and modulating Wnt/β-catenin signaling. Its HMG domain bends DNA ~80° and heterodimerizes with OCT4 on compressed Sox/Oct motifs to activate endodermal genes, whereas a canonical motif configuration supports pluripotency; single residue swaps at the OCT4 interface convert SOX17 into a reprogramming factor, demonstrating that the DNA-dependent dimer geometry dictates cell-fate outcome [PMID:19328208, PMID:21472822, PMID:23474895]. SOX17 represses Wnt/β-catenin transcriptional activity through multiple mechanisms—promoting GSK3β-independent proteasomal degradation of β-catenin and TCF/LEF, directly binding the β-catenin promoter, and co-occupying Wnt-responsive enhancers where it can either synergize with or antagonize β-catenin/TCF depending on the locus [PMID:17875931, PMID:29970906, PMID:32894225]. In endothelial cells, SOX17 operates downstream of Wnt and upstream of Notch signaling to specify arterial identity, regulate blood–brain barrier integrity, drive endothelial regeneration via HIF1α-induced Cyclin E1 activation, and maintain pulmonary vascular homeostasis—loss of endothelial SOX17 activates HGF/c-Met and E2F1 pathways that promote pulmonary arterial hypertension [PMID:24153254, PMID:31073164, PMID:30591003, PMID:36205124, PMID:37737027]."},"prefetch_data":{"uniprot":{"accession":"Q9H6I2","full_name":"Transcription factor SOX-17","aliases":[],"length_aa":414,"mass_kda":44.1,"function":"Acts as a transcription regulator that binds target promoter DNA (PubMed:33952808). Binds to the sequences 5'-AACAAT-'3 or 5'-AACAAAG-3'. Modulates transcriptional regulation via WNT3A. Inhibits Wnt signaling. Promotes degradation of activated CTNNB1. Plays a key role in the regulation of embryonic development. Required for normal development of the definitive gut endoderm. Required for normal looping of the embryonic heart tube. Plays an important role in embryonic and postnatal vascular development, including development of arteries. Plays an important role in postnatal angiogenesis, where it is functionally redundant with SOX18. Required for the generation and maintenance of fetal hematopoietic stem cells, and for fetal hematopoiesis. Probable transcriptional activator in the premeiotic germ cells","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/Q9H6I2/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/SOX17","classification":"Not Classified","n_dependent_lines":18,"n_total_lines":1208,"dependency_fraction":0.014900662251655629},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/SOX17","total_profiled":1310},"omim":[{"mim_id":"621248","title":"PULMONARY HYPERTENSION, PRIMARY, 7; PPH7","url":"https://www.omim.org/entry/621248"},{"mim_id":"620997","title":"SEMAPHORIN 3G; SEMA3G","url":"https://www.omim.org/entry/620997"},{"mim_id":"613674","title":"VESICOURETERAL REFLUX 3; VUR3","url":"https://www.omim.org/entry/613674"},{"mim_id":"612587","title":"ANEURYSM, INTRACRANIAL BERRY, 10; ANIB10","url":"https://www.omim.org/entry/612587"},{"mim_id":"612202","title":"SRY-BOX 7; SOX7","url":"https://www.omim.org/entry/612202"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Nucleoplasm","reliability":"Approved"},{"location":"Nuclear membrane","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"adipose tissue","ntpm":46.8}],"url":"https://www.proteinatlas.org/search/SOX17"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"Q9H6I2","domains":[{"cath_id":"1.10.30.10","chopping":"71-132","consensus_level":"high","plddt":97.8611,"start":71,"end":132}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9H6I2","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9H6I2-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9H6I2-F1-predicted_aligned_error_v6.png","plddt_mean":57.38},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=SOX17","jax_strain_url":"https://www.jax.org/strain/search?query=SOX17"},"sequence":{"accession":"Q9H6I2","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9H6I2.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9H6I2/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9H6I2"}},"corpus_meta":[{"pmid":"25543152","id":"PMC_25543152","title":"SOX17 is a critical specifier of human primordial germ cell fate.","date":"2014","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/25543152","citation_count":653,"is_preprint":false},{"pmid":"17875931","id":"PMC_17875931","title":"Sox17 and Sox4 differentially regulate beta-catenin/T-cell factor activity and proliferation of colon carcinoma cells.","date":"2007","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/17875931","citation_count":287,"is_preprint":false},{"pmid":"24153254","id":"PMC_24153254","title":"Sox17 is indispensable for acquisition and maintenance of arterial identity.","date":"2013","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/24153254","citation_count":234,"is_preprint":false},{"pmid":"21146513","id":"PMC_21146513","title":"The primitive endoderm lineage of the mouse blastocyst: sequential transcription factor activation and regulation of differentiation by Sox17.","date":"2010","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/21146513","citation_count":184,"is_preprint":false},{"pmid":"16895970","id":"PMC_16895970","title":"Redundant roles of Sox17 and Sox18 in postnatal angiogenesis in mice.","date":"2006","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/16895970","citation_count":174,"is_preprint":false},{"pmid":"23474895","id":"PMC_23474895","title":"Oct4 switches partnering from Sox2 to Sox17 to reinterpret the enhancer code and specify endoderm.","date":"2013","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/23474895","citation_count":155,"is_preprint":false},{"pmid":"17610846","id":"PMC_17610846","title":"Redundant roles of Sox17 and Sox18 in early cardiovascular development of mouse embryos.","date":"2007","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/17610846","citation_count":154,"is_preprint":false},{"pmid":"23604320","id":"PMC_23604320","title":"The expression of Sox17 identifies and regulates haemogenic endothelium.","date":"2013","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/23604320","citation_count":133,"is_preprint":false},{"pmid":"20716954","id":"PMC_20716954","title":"SOX17 antagonizes WNT/β-catenin signaling pathway in hepatocellular carcinoma.","date":"2010","source":"Epigenetics","url":"https://pubmed.ncbi.nlm.nih.gov/20716954","citation_count":123,"is_preprint":false},{"pmid":"30029678","id":"PMC_30029678","title":"Rare variants in SOX17 are associated with pulmonary arterial hypertension with congenital heart disease.","date":"2018","source":"Genome medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30029678","citation_count":119,"is_preprint":false},{"pmid":"16988043","id":"PMC_16988043","title":"Identification of Sox17 as a transcription factor that regulates oligodendrocyte development.","date":"2006","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/16988043","citation_count":117,"is_preprint":false},{"pmid":"21362573","id":"PMC_21362573","title":"Targeting SOX17 in human embryonic stem cells creates unique strategies for isolating and analyzing developing endoderm.","date":"2011","source":"Cell stem cell","url":"https://pubmed.ncbi.nlm.nih.gov/21362573","citation_count":116,"is_preprint":false},{"pmid":"31073164","id":"PMC_31073164","title":"Sox17 is required for endothelial regeneration following inflammation-induced vascular injury.","date":"2019","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/31073164","citation_count":108,"is_preprint":false},{"pmid":"21828271","id":"PMC_21828271","title":"Sox17 expression confers self-renewal potential and fetal stem cell characteristics upon adult hematopoietic progenitors.","date":"2011","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/21828271","citation_count":104,"is_preprint":false},{"pmid":"11786926","id":"PMC_11786926","title":"Molecular cloning and characterization of human SOX17.","date":"2002","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/11786926","citation_count":100,"is_preprint":false},{"pmid":"23241958","id":"PMC_23241958","title":"Sox17 promotes tumor angiogenesis and destabilizes tumor vessels in mice.","date":"2012","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/23241958","citation_count":95,"is_preprint":false},{"pmid":"19736317","id":"PMC_19736317","title":"Interplay of Oct4 with Sox2 and Sox17: a molecular switch from stem cell pluripotency to specifying a cardiac fate.","date":"2009","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/19736317","citation_count":92,"is_preprint":false},{"pmid":"22961961","id":"PMC_22961961","title":"Genome-wide association study of intracranial aneurysms confirms role of Anril and SOX17 in disease risk.","date":"2012","source":"Stroke","url":"https://pubmed.ncbi.nlm.nih.gov/22961961","citation_count":92,"is_preprint":false},{"pmid":"27081925","id":"PMC_27081925","title":"The toxin biliatresone causes mouse extrahepatic cholangiocyte damage and fibrosis through decreased glutathione and SOX17.","date":"2016","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/27081925","citation_count":90,"is_preprint":false},{"pmid":"28237397","id":"PMC_28237397","title":"SOX17 regulates cholangiocyte differentiation and acts as a tumor suppressor in cholangiocarcinoma.","date":"2017","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/28237397","citation_count":88,"is_preprint":false},{"pmid":"23169777","id":"PMC_23169777","title":"Role of SOX17 in hematopoietic development from human embryonic stem cells.","date":"2012","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/23169777","citation_count":88,"is_preprint":false},{"pmid":"21472822","id":"PMC_21472822","title":"Conversion of Sox17 into a pluripotency reprogramming factor by reengineering its association with Oct4 on DNA.","date":"2011","source":"Stem cells (Dayton, Ohio)","url":"https://pubmed.ncbi.nlm.nih.gov/21472822","citation_count":87,"is_preprint":false},{"pmid":"19515696","id":"PMC_19515696","title":"Sox7 and Sox17 are strain-specific modifiers of the lymphangiogenic defects caused by Sox18 dysfunction in mice.","date":"2009","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/19515696","citation_count":84,"is_preprint":false},{"pmid":"26630461","id":"PMC_26630461","title":"Sox7, Sox17, and Sox18 Cooperatively Regulate Vascular Development in the Mouse Retina.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26630461","citation_count":80,"is_preprint":false},{"pmid":"20043076","id":"PMC_20043076","title":"Integrative genomic analyses of CXCR4: transcriptional regulation of CXCR4 based on TGFbeta, Nodal, Activin signaling and POU5F1, FOXA2, FOXC2, FOXH1, SOX17, and GFI1 transcription factors.","date":"2010","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/20043076","citation_count":80,"is_preprint":false},{"pmid":"26741346","id":"PMC_26741346","title":"SOX17 promoter methylation in plasma circulating tumor DNA of patients with non-small cell lung cancer.","date":"2016","source":"Clinical chemistry and laboratory medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26741346","citation_count":76,"is_preprint":false},{"pmid":"24755984","id":"PMC_24755984","title":"Notch pathway targets proangiogenic regulator Sox17 to restrict angiogenesis.","date":"2014","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/24755984","citation_count":75,"is_preprint":false},{"pmid":"38418875","id":"PMC_38418875","title":"SOX17 enables immune evasion of early colorectal adenomas and cancers.","date":"2024","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/38418875","citation_count":74,"is_preprint":false},{"pmid":"30591003","id":"PMC_30591003","title":"Fine-Tuning of Sox17 and Canonical Wnt Coordinates the Permeability Properties of the Blood-Brain Barrier.","date":"2019","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/30591003","citation_count":70,"is_preprint":false},{"pmid":"19328208","id":"PMC_19328208","title":"The structure of Sox17 bound to DNA reveals a conserved bending topology but selective protein interaction platforms.","date":"2009","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/19328208","citation_count":68,"is_preprint":false},{"pmid":"19549530","id":"PMC_19549530","title":"Induction and down-regulation of Sox17 and its possible roles during the course of gastrointestinal tumorigenesis.","date":"2009","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/19549530","citation_count":67,"is_preprint":false},{"pmid":"15220343","id":"PMC_15220343","title":"SOX7 and SOX17 regulate the parietal endoderm-specific enhancer activity of mouse laminin alpha1 gene.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15220343","citation_count":67,"is_preprint":false},{"pmid":"25596186","id":"PMC_25596186","title":"Deficiency of endothelium-specific transcription factor Sox17 induces intracranial aneurysm.","date":"2015","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/25596186","citation_count":65,"is_preprint":false},{"pmid":"22921431","id":"PMC_22921431","title":"Inhibition of SOX17 by microRNA 141 and methylation activates the WNT signaling pathway in esophageal cancer.","date":"2012","source":"The Journal of molecular diagnostics : JMD","url":"https://pubmed.ncbi.nlm.nih.gov/22921431","citation_count":60,"is_preprint":false},{"pmid":"25868860","id":"PMC_25868860","title":"The SOX17/miR-371-5p/SOX2 axis inhibits EMT, stem cell properties and metastasis in colorectal cancer.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/25868860","citation_count":56,"is_preprint":false},{"pmid":"19369635","id":"PMC_19369635","title":"Differential expression of SOX2 and SOX17 in testicular germ cell tumors.","date":"2009","source":"American journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/19369635","citation_count":56,"is_preprint":false},{"pmid":"23293295","id":"PMC_23293295","title":"Sox17 haploinsufficiency results in perinatal biliary atresia and hepatitis in C57BL/6 background mice.","date":"2013","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/23293295","citation_count":55,"is_preprint":false},{"pmid":"19548312","id":"PMC_19548312","title":"Sox17-2A-iCre: a knock-in mouse line expressing Cre recombinase in endoderm and vascular endothelial cells.","date":"2009","source":"Genesis (New York, N.Y. : 2000)","url":"https://pubmed.ncbi.nlm.nih.gov/19548312","citation_count":54,"is_preprint":false},{"pmid":"29970906","id":"PMC_29970906","title":"SOX17 restrains proliferation and tumor formation by down-regulating activity of the Wnt/β-catenin signaling pathway via trans-suppressing β-catenin in cervical cancer.","date":"2018","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/29970906","citation_count":52,"is_preprint":false},{"pmid":"22846201","id":"PMC_22846201","title":"SOX17 methylation inhibits its antagonism of Wnt signaling pathway in lung cancer.","date":"2012","source":"Discovery medicine","url":"https://pubmed.ncbi.nlm.nih.gov/22846201","citation_count":52,"is_preprint":false},{"pmid":"21514720","id":"PMC_21514720","title":"Sox17 regulates proliferation and cell cycle during gastric cancer progression.","date":"2011","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/21514720","citation_count":51,"is_preprint":false},{"pmid":"25373912","id":"PMC_25373912","title":"Sox17-mediated XEN cell conversion identifies dynamic networks controlling cell-fate decisions in embryo-derived stem cells.","date":"2014","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/25373912","citation_count":51,"is_preprint":false},{"pmid":"20960469","id":"PMC_20960469","title":"Mutations in SOX17 are associated with congenital anomalies of the kidney and the urinary tract.","date":"2010","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/20960469","citation_count":51,"is_preprint":false},{"pmid":"33608411","id":"PMC_33608411","title":"GATA transcription factors, SOX17 and TFAP2C, drive the human germ-cell specification program.","date":"2021","source":"Life science alliance","url":"https://pubmed.ncbi.nlm.nih.gov/33608411","citation_count":50,"is_preprint":false},{"pmid":"22865702","id":"PMC_22865702","title":"Dual lineage-specific expression of Sox17 during mouse embryogenesis.","date":"2012","source":"Stem cells (Dayton, Ohio)","url":"https://pubmed.ncbi.nlm.nih.gov/22865702","citation_count":50,"is_preprint":false},{"pmid":"31419525","id":"PMC_31419525","title":"SOX17 in cellular reprogramming and cancer.","date":"2019","source":"Seminars in cancer biology","url":"https://pubmed.ncbi.nlm.nih.gov/31419525","citation_count":49,"is_preprint":false},{"pmid":"19415628","id":"PMC_19415628","title":"Generation of a mouse line expressing Sox17-driven Cre recombinase with specific activity in arteries.","date":"2009","source":"Genesis (New York, N.Y. : 2000)","url":"https://pubmed.ncbi.nlm.nih.gov/19415628","citation_count":45,"is_preprint":false},{"pmid":"27738313","id":"PMC_27738313","title":"SOX17 is a tumor suppressor in endometrial cancer.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27738313","citation_count":45,"is_preprint":false},{"pmid":"11518513","id":"PMC_11518513","title":"VegT activation of Sox17 at the midblastula transition alters the response to nodal signals in the vegetal endoderm domain.","date":"2001","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/11518513","citation_count":44,"is_preprint":false},{"pmid":"35380877","id":"PMC_35380877","title":"The transcription factor PAX8 promotes angiogenesis in ovarian cancer through interaction with SOX17.","date":"2022","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/35380877","citation_count":43,"is_preprint":false},{"pmid":"22161215","id":"PMC_22161215","title":"Hypermethylation of Sox17 gene is useful as a molecular diagnostic application in early gastric cancer.","date":"2011","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/22161215","citation_count":43,"is_preprint":false},{"pmid":"23474492","id":"PMC_23474492","title":"Modulation of the Wnt/beta-catenin pathway in human oligodendroglioma cells by Sox17 regulates proliferation and differentiation.","date":"2013","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/23474492","citation_count":42,"is_preprint":false},{"pmid":"21760905","id":"PMC_21760905","title":"Efficient and directive generation of two distinct endoderm lineages from human ESCs and iPSCs by differentiation stage-specific SOX17 transduction.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21760905","citation_count":41,"is_preprint":false},{"pmid":"30777052","id":"PMC_30777052","title":"SOX17 overexpression sensitizes chemoradiation response in esophageal cancer by transcriptional down-regulation of DNA repair and damage response genes.","date":"2019","source":"Journal of biomedical science","url":"https://pubmed.ncbi.nlm.nih.gov/30777052","citation_count":40,"is_preprint":false},{"pmid":"36205124","id":"PMC_36205124","title":"Sox17 Deficiency Promotes Pulmonary Arterial Hypertension via HGF/c-Met Signaling.","date":"2022","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/36205124","citation_count":40,"is_preprint":false},{"pmid":"32894225","id":"PMC_32894225","title":"Sox17 and β-catenin co-occupy Wnt-responsive enhancers to govern the endoderm gene regulatory network.","date":"2020","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/32894225","citation_count":38,"is_preprint":false},{"pmid":"19238729","id":"PMC_19238729","title":"Sox17 facilitates the differentiation of mouse embryonic stem cells into primitive and definitive endoderm in vitro.","date":"2008","source":"Development, growth & differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/19238729","citation_count":36,"is_preprint":false},{"pmid":"31583686","id":"PMC_31583686","title":"Unique and redundant roles of SOX2 and SOX17 in regulating the germ cell tumor fate.","date":"2019","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/31583686","citation_count":36,"is_preprint":false},{"pmid":"33596423","id":"PMC_33596423","title":"SOX17 integrates HOXA and arterial programs in hemogenic endothelium to drive definitive lympho-myeloid hematopoiesis.","date":"2021","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/33596423","citation_count":33,"is_preprint":false},{"pmid":"22121118","id":"PMC_22121118","title":"The Sox17-mCherry fusion mouse line allows visualization of endoderm and vascular endothelial development.","date":"2011","source":"Genesis (New York, N.Y. : 2000)","url":"https://pubmed.ncbi.nlm.nih.gov/22121118","citation_count":33,"is_preprint":false},{"pmid":"23918253","id":"PMC_23918253","title":"SOX17 is expressed in regenerating oligodendrocytes in experimental models of demyelination and in multiple sclerosis.","date":"2013","source":"Glia","url":"https://pubmed.ncbi.nlm.nih.gov/23918253","citation_count":32,"is_preprint":false},{"pmid":"28381471","id":"PMC_28381471","title":"SOX17 Regulates Conversion of Human Fibroblasts Into Endothelial Cells and Erythroblasts by Dedifferentiation Into CD34+ Progenitor Cells.","date":"2017","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/28381471","citation_count":32,"is_preprint":false},{"pmid":"37066790","id":"PMC_37066790","title":"SOX17 Enhancer Variants Disrupt Transcription Factor Binding And Enhancer Inactivity Drives Pulmonary Hypertension.","date":"2023","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/37066790","citation_count":31,"is_preprint":false},{"pmid":"31420575","id":"PMC_31420575","title":"Endocardium differentiation through Sox17 expression in endocardium precursor cells regulates heart development in mice.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/31420575","citation_count":31,"is_preprint":false},{"pmid":"20228271","id":"PMC_20228271","title":"Contrasting effects of Sox17- and Sox18-sustained expression at the onset of blood specification.","date":"2010","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/20228271","citation_count":31,"is_preprint":false},{"pmid":"36919784","id":"PMC_36919784","title":"SOX17 is a Critical Factor in Maintaining Endothelial Function in Pulmonary Hypertension by an Exosome-Mediated Autocrine Manner.","date":"2023","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/36919784","citation_count":30,"is_preprint":false},{"pmid":"21457403","id":"PMC_21457403","title":"CD133 is a marker of gland-forming cells in gastric tumors and Sox17 is involved in its regulation.","date":"2011","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/21457403","citation_count":30,"is_preprint":false},{"pmid":"36913491","id":"PMC_36913491","title":"SOX17 Deficiency Mediates Pulmonary Hypertension: At the Crossroads of Sex, Metabolism, and Genetics.","date":"2023","source":"American journal of respiratory and critical care medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36913491","citation_count":28,"is_preprint":false},{"pmid":"32921258","id":"PMC_32921258","title":"Sox17 Controls Emergence and Remodeling of Nestin-Expressing Coronary Vessels.","date":"2020","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/32921258","citation_count":27,"is_preprint":false},{"pmid":"12659838","id":"PMC_12659838","title":"Molecular cloning and expression of Sox17 in gonads during sex reversal in the rice field eel, a teleost fish with a characteristic of natural sex transformation.","date":"2003","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/12659838","citation_count":27,"is_preprint":false},{"pmid":"24662049","id":"PMC_24662049","title":"Sox17-mediated maintenance of fetal intra-aortic hematopoietic cell clusters.","date":"2014","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/24662049","citation_count":26,"is_preprint":false},{"pmid":"23884956","id":"PMC_23884956","title":"Transgenic overexpression of Sox17 promotes oligodendrocyte development and attenuates demyelination.","date":"2013","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/23884956","citation_count":26,"is_preprint":false},{"pmid":"26411902","id":"PMC_26411902","title":"OCT4 Coordinates with WNT Signaling to Pre-pattern Chromatin at the SOX17 Locus during Human ES Cell Differentiation into Definitive Endoderm.","date":"2015","source":"Stem cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/26411902","citation_count":26,"is_preprint":false},{"pmid":"33632800","id":"PMC_33632800","title":"The pathophysiological role of novel pulmonary arterial hypertension gene SOX17.","date":"2021","source":"The European respiratory journal","url":"https://pubmed.ncbi.nlm.nih.gov/33632800","citation_count":25,"is_preprint":false},{"pmid":"36788073","id":"PMC_36788073","title":"Identifying SOX17 as a Sensitive and Specific Marker for Ovarian and Endometrial Carcinomas.","date":"2023","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/36788073","citation_count":25,"is_preprint":false},{"pmid":"24585688","id":"PMC_24585688","title":"Hhex and Cer1 mediate the Sox17 pathway for cardiac mesoderm formation in embryonic stem cells.","date":"2014","source":"Stem cells (Dayton, Ohio)","url":"https://pubmed.ncbi.nlm.nih.gov/24585688","citation_count":25,"is_preprint":false},{"pmid":"36344664","id":"PMC_36344664","title":"An organ-on-chip model of pulmonary arterial hypertension identifies a BMPR2-SOX17-prostacyclin signalling axis.","date":"2022","source":"Communications biology","url":"https://pubmed.ncbi.nlm.nih.gov/36344664","citation_count":24,"is_preprint":false},{"pmid":"28432216","id":"PMC_28432216","title":"Embryonic cholecystitis and defective gallbladder contraction in the Sox17-haploinsufficient mouse model of biliary atresia.","date":"2017","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/28432216","citation_count":24,"is_preprint":false},{"pmid":"25106407","id":"PMC_25106407","title":"Sox17 inhibits hepatocellular carcinoma progression by downregulation of KIF14 expression.","date":"2014","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25106407","citation_count":22,"is_preprint":false},{"pmid":"20925124","id":"PMC_20925124","title":"Sox17 and chordin are required for formation of Kupffer's vesicle and left-right asymmetry determination in zebrafish.","date":"2010","source":"Developmental dynamics : an official publication of the American Association of Anatomists","url":"https://pubmed.ncbi.nlm.nih.gov/20925124","citation_count":22,"is_preprint":false},{"pmid":"25144761","id":"PMC_25144761","title":"Sox17 regulates insulin secretion in the normal and pathologic mouse β cell.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25144761","citation_count":21,"is_preprint":false},{"pmid":"22132182","id":"PMC_22132182","title":"Involvement of histone acetylation of Sox17 and Foxa2 promoters during mouse definitive endoderm differentiation revealed by microRNA profiling.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22132182","citation_count":21,"is_preprint":false},{"pmid":"19084513","id":"PMC_19084513","title":"Functional analysis of the evolutionarily conserved cis-regulatory elements on the sox17 gene in zebrafish.","date":"2008","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/19084513","citation_count":21,"is_preprint":false},{"pmid":"33952808","id":"PMC_33952808","title":"SOX17 Loss-of-Function Mutation Underlying Familial Pulmonary Arterial Hypertension.","date":"2021","source":"International heart journal","url":"https://pubmed.ncbi.nlm.nih.gov/33952808","citation_count":20,"is_preprint":false},{"pmid":"31863486","id":"PMC_31863486","title":"MRP3-Mediated Chemoresistance in Cholangiocarcinoma: Target for Chemosensitization Through Restoring SOX17 Expression.","date":"2020","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/31863486","citation_count":20,"is_preprint":false},{"pmid":"36310172","id":"PMC_36310172","title":"Dysregulation of SOX17/NRF2 axis confers chemoradiotherapy resistance and emerges as a novel therapeutic target in esophageal squamous cell carcinoma.","date":"2022","source":"Journal of biomedical science","url":"https://pubmed.ncbi.nlm.nih.gov/36310172","citation_count":20,"is_preprint":false},{"pmid":"35124696","id":"PMC_35124696","title":"SOX17 and PAX8 constitute an actionable lineage-survival transcriptional complex in ovarian cancer.","date":"2022","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/35124696","citation_count":20,"is_preprint":false},{"pmid":"36853778","id":"PMC_36853778","title":"SOX17: A Highly Sensitive and Specific Immunomarker for Ovarian and Endometrial Carcinomas.","date":"2023","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/36853778","citation_count":19,"is_preprint":false},{"pmid":"31444787","id":"PMC_31444787","title":"SOX17 expression and its down-regulation by promoter methylation in cervical adenocarcinoma in situ and adenocarcinoma.","date":"2019","source":"Histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/31444787","citation_count":19,"is_preprint":false},{"pmid":"34006305","id":"PMC_34006305","title":"A novel tumor suppressor ASMTL-AS1 regulates the miR-1228-3p/SOX17/β-catenin axis in triple-negative breast cancer.","date":"2021","source":"Diagnostic pathology","url":"https://pubmed.ncbi.nlm.nih.gov/34006305","citation_count":18,"is_preprint":false},{"pmid":"38478109","id":"PMC_38478109","title":"Deubiquitinase UCHL1 promotes angiogenesis and blood-spinal cord barrier function recovery after spinal cord injury by stabilizing Sox17.","date":"2024","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/38478109","citation_count":17,"is_preprint":false},{"pmid":"27065754","id":"PMC_27065754","title":"SOX17 increases the cisplatin sensitivity of an endometrial cancer cell line.","date":"2016","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/27065754","citation_count":17,"is_preprint":false},{"pmid":"22984607","id":"PMC_22984607","title":"Elucidation of a novel pathway through which HDAC1 controls cardiomyocyte differentiation through expression of SOX-17 and BMP2.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22984607","citation_count":17,"is_preprint":false},{"pmid":"37737027","id":"PMC_37737027","title":"E2F1 Mediates SOX17 Deficiency-Induced Pulmonary Hypertension.","date":"2023","source":"Hypertension (Dallas, Tex. : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/37737027","citation_count":16,"is_preprint":false},{"pmid":"37866545","id":"PMC_37866545","title":"Compound AC1Q3QWB upregulates CDKN1A and SOX17 by interrupting the HOTAIR-EZH2 interaction and enhances the efficacy of tazemetostat in endometrial cancer.","date":"2023","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/37866545","citation_count":16,"is_preprint":false},{"pmid":"37611093","id":"PMC_37611093","title":"An engineered Sox17 induces somatic to neural stem cell fate transitions independently from pluripotency reprogramming.","date":"2023","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/37611093","citation_count":16,"is_preprint":false},{"pmid":"31996362","id":"PMC_31996362","title":"Gallbladder wall abnormality in biliary atresia of mouse Sox17+/- neonates and human infants.","date":"2020","source":"Disease models & mechanisms","url":"https://pubmed.ncbi.nlm.nih.gov/31996362","citation_count":16,"is_preprint":false},{"pmid":"17719026","id":"PMC_17719026","title":"Regulation of the Xenopus Xsox17alpha(1) promoter by co-operating VegT and Sox17 sites.","date":"2007","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/17719026","citation_count":16,"is_preprint":false},{"pmid":"30928652","id":"PMC_30928652","title":"Endothelial Sox17 promotes allergic airway inflammation.","date":"2019","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30928652","citation_count":16,"is_preprint":false},{"pmid":"25141153","id":"PMC_25141153","title":"Sox17 regulates liver lipid metabolism and adaptation to fasting.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25141153","citation_count":15,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":49726,"output_tokens":10431,"usd":0.152821},"stage2":{"model":"claude-opus-4-6","input_tokens":14553,"output_tokens":9470,"usd":0.464272},"total_usd":0.617093,"stage1_batch_id":"msgbatch_011rkcQdVV1RaFq9XhcG6df6","stage2_batch_id":"msgbatch_01RzgrJafdF4EWHhj5mNi6dh","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2007,\n      \"finding\": \"SOX17 physically interacts with TCF/LEF family members via its HMG box domain and with β-catenin, promoting proteasomal degradation of both β-catenin and TCF proteins via a glycogen synthase kinase 3β-independent mechanism, thereby repressing β-catenin/TCF transcriptional activity and inhibiting proliferation in colon carcinoma cells.\",\n      \"method\": \"Co-immunoprecipitation, gain- and loss-of-function experiments, proteasome inhibitor treatment, luciferase reporter assay, dose-response overexpression in SW480 cells\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (Co-IP, functional rescue, reporter assay, proteasome inhibitor) in a single rigorous study\",\n      \"pmids\": [\"17875931\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"The crystal structure of the SOX17 HMG domain bound to DNA shows it bends DNA ~80° by targeting the minor groove, similar to SOX2, but presents an altered charge distribution at the Oct-factor interaction interface, predicting differential co-factor recruitment relative to SOX2.\",\n      \"method\": \"X-ray crystallography at 2.7 Å resolution; DNA-binding affinity measurements\",\n      \"journal\": \"Journal of molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure with functional validation of DNA affinity\",\n      \"pmids\": [\"19328208\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"SOX17 and SOX2 exhibit inverse heterodimerization preferences with OCT4 on canonical vs. compressed Sox/Oct DNA motifs; exchange of single amino acids at the OCT4 interaction interface converts SOX17 into a pluripotency reprogramming factor (SOX17EK) and abolishes SOX2 reprogramming activity (SOX2KE), demonstrating that the DNA-dependent Sox/Oct dimer configuration determines cell-fate outcome.\",\n      \"method\": \"Structure-based mutagenesis, somatic cell reprogramming assays, ESC overexpression, DNA-binding studies\",\n      \"journal\": \"Stem cells (Dayton, Ohio)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mutagenesis combined with functional reprogramming assay and structural rationale, replicated concept in EMBO 2013\",\n      \"pmids\": [\"21472822\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"SOX17 partners with OCT4 and binds a 'compressed' Sox/Oct motif that earmarks endodermal genes, in contrast to the canonical motif used by the OCT4-SOX2 complex in pluripotency; the compressed motif is required for proper endodermal gene expression in a differentiation assay.\",\n      \"method\": \"ChIP-seq, DNA motif analysis, endodermal differentiation reporter assay, point-mutant protein studies\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — genomic binding data combined with mutagenesis and functional differentiation assay\",\n      \"pmids\": [\"23474895\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"SOX17 is the key transcriptional regulator of human primordial germ cell (hPGC) fate specification, whereas in mouse PGC specification this role is played by SOX2; BLIMP1 acts to repress somatic/endodermal genes during hPGCLC specification.\",\n      \"method\": \"hPGCLC specification from human pluripotent stem cells, loss-of-function (siRNA/knockout), gain-of-function, transcriptome analysis, cell surface marker characterization\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods, highly cited foundational study\",\n      \"pmids\": [\"25543152\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Endothelial-specific inactivation of Sox17 in mice causes loss of arterial identity and vascular remodeling defects; mechanistically, Sox17 acts downstream of canonical Wnt signaling and upstream of the Notch signaling system in arterial specification.\",\n      \"method\": \"Conditional endothelial knockout mice, epistasis experiments with Wnt and Notch pathway components, postnatal retina vascular analysis\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean conditional KO with defined molecular epistasis (Wnt upstream, Notch downstream)\",\n      \"pmids\": [\"24153254\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"SOX17 is expressed in haemogenic endothelium and regulates hematopoietic stem cell development through the Notch signalling pathway; Sox17 deletion abolishes haemogenic endothelial development in vivo and in the ESC differentiation model.\",\n      \"method\": \"Sox17-GFP reporter mice, ESC differentiation model, conditional knockout, Notch pathway analysis\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal approaches (reporter, KO, ESC model) in a single study\",\n      \"pmids\": [\"23604320\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"SOX17 binds to two SOX-binding sites within the parietal endoderm-specific enhancer of the mouse laminin α1 (Lama1) gene and trans-activates transcription in a manner dependent on HMG box-mediated DNA binding, with synergistic cooperation between the two SOX sites and adjacent Sp1/Sp3 and NF-Y binding sites.\",\n      \"method\": \"Luciferase reporter assay, EMSA, mutational analysis, Northern blot, F9 cell differentiation model\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro DNA binding (EMSA) plus functional reporter assay with mutagenesis\",\n      \"pmids\": [\"15220343\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Sox17 controls both cell cycle exit and differentiation of oligodendrocyte progenitor cells (OPCs); siRNA-mediated knockdown increases OPC proliferation and decreases lineage progression, while overexpression enhances myelin gene expression and directly stimulates MBP gene promoter activity.\",\n      \"method\": \"siRNA knockdown, overexpression, FACS purification, promoter reporter assay, immunostaining\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal gain/loss-of-function with promoter reporter and multiple cellular readouts\",\n      \"pmids\": [\"16988043\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"HIF1α transcriptionally activates Sox17 expression during endotoxemia; Sox17 in turn upregulates Cyclin E1 to drive endothelial cell proliferation and regeneration after inflammatory vascular injury; genetic lineage tracing shows native endothelium is the primary source of repopulating endothelial cells.\",\n      \"method\": \"Endothelial-specific Sox17 deletion and overexpression, genetic lineage tracing, ChIP, CyclinE1 functional studies, endotoxemia mouse model\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — conditional KO/OE with mechanism (HIF1α→Sox17→CyclinE1) supported by multiple orthogonal experiments\",\n      \"pmids\": [\"31073164\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Sox17 expression in adult hematopoietic stem cells (HSCs) and transiently reconstituting progenitors is sufficient to confer fetal HSC characteristics including increased self-renewal potential and fetal surface marker expression; long-term ectopic Sox17 expression eventually leads to leukemogenesis.\",\n      \"method\": \"Retroviral Sox17 overexpression in adult HSCs, bone marrow transplantation/reconstitution assay, gene expression profiling\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — gain-of-function in primary HSCs with in vivo reconstitution readout\",\n      \"pmids\": [\"21828271\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Notch signaling suppresses Sox17 expression predominantly at the post-transcriptional level in stalk cells; Sox17 promotes endothelial tip cell behavior by destabilizing junctions and rearranging cytoskeletal structure, and upregulates tip-cell-enriched genes including VEGFR2; endothelial Sox17 deletion rescues hyperbranching caused by Notch inhibition.\",\n      \"method\": \"Endothelial-specific Sox17 deletion/overexpression mice, Notch intracellular domain overexpression, Dll4 blockade, retinal angiogenesis analysis, gene expression studies\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis between Notch and Sox17 validated with multiple in vivo and in vitro approaches\",\n      \"pmids\": [\"24755984\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Sox17 regulates blood-brain barrier (BBB) permeability; endothelial-specific Sox17 inactivation increases brain microvascular permeability; mechanistically, Sox17 acts as a positive inducer of Wnt/β-catenin signaling (members of the pathway are downstream targets), and inhibition of the β-catenin destruction complex rescues the permeability defect caused by Sox17 loss.\",\n      \"method\": \"Endothelial-specific Sox17 knockout mice, RNA-seq of brain endothelial cells, β-catenin stabilization rescue experiments, reporter mice\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — conditional KO with RNA-seq and genetic rescue experiments\",\n      \"pmids\": [\"30591003\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"In Xenopus, Sox17 and β-catenin co-occupy hundreds of Wnt-responsive enhancers in the endoderm; on some enhancers Sox17 and β-catenin synergistically activate transcription independently of TCF factors, while on others Sox17 represses β-catenin/TCF-mediated transcription; Sox17 acts as a tissue-specific modifier of Wnt responses to specify endoderm while repressing mesectoderm fates.\",\n      \"method\": \"ChIP-seq, ATAC-seq, epistasis experiments, luciferase reporter assays, Xenopus gastrula genomic approaches\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — genome-wide binding data plus epistasis and reporter assays with orthogonal methods\",\n      \"pmids\": [\"32894225\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"SOX17 physically interacts with PAX8 in ovarian cancer cells; the two transcription factors co-occupy overlapping genomic regions and regulate a common set of downstream genes including those involved in cell cycle and tissue morphogenesis; together they suppress SERPINE1 expression to promote secretion of pro-angiogenic factors.\",\n      \"method\": \"PAX8 protein complex purification (pulldown), Co-IP, ChIP-seq, siRNA depletion, in vitro tube formation assay, mouse xenograft model\",\n      \"journal\": \"Science signaling\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal protein purification + genomic co-occupancy + functional assays in two cell contexts\",\n      \"pmids\": [\"35380877\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Sox17 deficiency in pulmonary endothelial cells activates HGF/c-Met signaling; Sox17-deficient lung endothelial cells upregulate HGF (a c-Met ligand), and pharmacological inhibition of HGF/c-Met attenuates PAH features in both preventive and therapeutic settings in mouse models.\",\n      \"method\": \"EC-specific Sox17 deletion mice, transcriptomic profiling, pharmacological HGF/c-Met inhibition, hypoxia model of PAH\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — conditional KO with transcriptomic mechanism and pharmacological rescue\",\n      \"pmids\": [\"36205124\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"SOX17 directly activates CDX2 expression in hemogenic endothelium (HE), which upregulates HOXA cluster genes; SOX17 also activates Notch signaling and is required for specification of HE with lympho-myeloid potential and arterial HE identity (DLL4+CXCR4+ phenotype).\",\n      \"method\": \"SOX17-knockout and SOX17-inducible hPSCs, molecular profiling, ChIP, transcriptomic analysis\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — KO and inducible OE in human PSCs with direct target (CDX2) identified by ChIP\",\n      \"pmids\": [\"33596423\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"SOX17 trans-suppresses β-catenin expression by directly binding to the β-catenin promoter, thereby inhibiting Wnt/β-catenin pathway activity and restraining proliferation in cervical cancer cells.\",\n      \"method\": \"Luciferase reporter assay, quantitative ChIP (qChIP), TOP/FOP-Flash assay, Western blot, colony formation assay, nude mouse tumor model\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct promoter binding confirmed by ChIP plus functional reporter and mutagenesis\",\n      \"pmids\": [\"29970906\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Sox17 in tumor endothelial cells promotes endothelial sprouting and upregulates VEGFR2 expression in a cell-intrinsic manner; it also increases tumor-associated CD11b+Gr-1+ myeloid cell recruitment; Sox17 deletion in tumor ECs normalizes tumor vessels and reduces tumor growth.\",\n      \"method\": \"Sox17 conditional deletion and overexpression in endothelial cells, tumor transplantation models, VEGFR2 expression analysis\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — conditional gain/loss-of-function with defined molecular (VEGFR2) and cellular phenotypic readouts\",\n      \"pmids\": [\"23241958\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Forced expression of Sox17 in mouse ESC-derived AGM CD45low c-Kit high intra-aortic cluster cells maintains their cluster-forming and HSC identity in vitro and long-term reconstitution activity in vivo; shutdown of Sox17 results in immediate hematopoietic differentiation, indicating Sox17 controls the HSC fate decision between self-renewal and differentiation.\",\n      \"method\": \"Retroviral Sox17 overexpression with inducible shutdown, stromal co-culture cluster assay, long-term bone marrow reconstitution\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — inducible gain/loss-of-function with in vivo reconstitution readout\",\n      \"pmids\": [\"24662049\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"SOX17 is required for cardiac mesoderm/cardiomyocyte differentiation in mouse ESCs; downstream targets Hhex and Cer1 are indispensable components of this pathway—SOX17 directly activates Cer1 transcription (demonstrated by ChIP and luciferase reporter), Hhex is required for Cer1 expression, and forced Cer1 expression rescues cardiac differentiation in Hhex-deficient cells.\",\n      \"method\": \"RNAi, genome-wide profiling, ChIP, luciferase reporter assays, rescue experiments in ESC differentiation model\",\n      \"journal\": \"Stem cells (Dayton, Ohio)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct target identification by ChIP plus epistasis and functional rescue\",\n      \"pmids\": [\"24585688\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Sox17 acts in autoregulatory and feedforward gene regulatory network motifs during ESC-to-XEN cell conversion; forced Sox17 expression in ESCs drives them toward extraembryonic endoderm (XEN) identity with distinct intermediate states.\",\n      \"method\": \"Forced Sox17 expression in ESCs, embryo injection functional test, transcriptomic analysis of intermediate states\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — single study with functional conversion and network analysis but limited biochemical mechanistic detail\",\n      \"pmids\": [\"25373912\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"In endometrial cancer cells, SOX17 binds to the MAML3 promoter and downregulates MAML3 transcription; MAML3 is a co-activator of β-catenin-mediated transcription and requires its C-terminal region for SOX17 binding; the SOX17-MAML3 interaction was confirmed by Co-IP in cell nuclei.\",\n      \"method\": \"Co-IP, luciferase reporter assay (MAML3 promoter binding), Western blot, in vivo xenograft model\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — Co-IP and reporter assay, single study\",\n      \"pmids\": [\"27738313\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Sox17 overexpression in gastric cancer cells suppresses Wnt/β-catenin transcriptional activity and colony formation; Sox17 is induced by Wnt activation in early gastric tumors but silenced by DNA methylation during malignant progression; transgenic Sox17 expression suppresses dysplastic tumor development in K19-Wnt1/C2mE mice.\",\n      \"method\": \"Sox17 transfection, luciferase reporter assay, demethylating agent treatment, transgenic mice\",\n      \"journal\": \"Gastroenterology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional reporter + in vivo transgenic model, single lab\",\n      \"pmids\": [\"19549530\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"PAH risk alleles upstream of SOX17 reduce endothelial SOX17 expression through differential binding of transcription factors HOXA5 and ROR-α (confirmed by EMSA and antibody-EMSA); SOX17 silencing in hPAECs alters extracellular matrix regulation, increases apoptosis, proliferation, and disrupts barrier function; SOX17 enhancer knockout in mice exacerbates hypoxia-induced pulmonary hypertension.\",\n      \"method\": \"CRISPR enhancer deletion, siRNA, EMSA, RNA-seq, in vivo pulmonary hypertension mouse model\",\n      \"journal\": \"Circulation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — EMSA-confirmed TF binding to disease variants plus multiple functional readouts in vivo and in vitro\",\n      \"pmids\": [\"37066790\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"E2F1 signaling mediates SOX17 deficiency-induced endothelial dysfunction and pulmonary hypertension; loss of endothelial Sox17 upregulates E2F1-driven cell cycle programming; pharmacological E2F1 inhibition in Sox17 EC-deficient mice attenuates pulmonary hypertension.\",\n      \"method\": \"Tie2Cre-mediated Sox17 knockdown, EC-specific Sox17 deletion, scRNA-seq, RNA-seq, luciferase assay, pharmacological E2F1 inhibition in vivo\",\n      \"journal\": \"Hypertension (Dallas, Tex. : 1979)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — conditional KO with pharmacological rescue identifying E2F1 as downstream mediator\",\n      \"pmids\": [\"37066790\", \"37737027\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"SOX17 deficiency increases HIF2α levels in pulmonary endothelial cells; increased SOX17 promotes oxidative phosphorylation and mitochondrial function partly counteracted by HIF2α overexpression; the pathological estrogen metabolite 16α-hydroxyestrone represses SOX17 promoter activity to exacerbate pulmonary hypertension.\",\n      \"method\": \"Seahorse metabolic assay, promoter luciferase assay, Tie2-Sox17 KO and Tg mice, chronic hypoxia model, untargeted proteomics\",\n      \"journal\": \"American journal of respiratory and critical care medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — mechanistic promoter assay + metabolic assays + in vivo genetic models\",\n      \"pmids\": [\"36913491\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"SOX17 suppresses the ability of colorectal tumor cells to sense and respond to IFNγ (preventing anti-tumour T cell responses) and drives differentiation toward LGR5- immune-evasive cells with lower MHC-I expression by engaging a fetal intestinal programme; SOX17 loss in AKP organoid tumors markedly reduces in vivo persistence and elicits IFNγ-producing CD8+ T cell infiltrates.\",\n      \"method\": \"SOX17-null organoid transplantation into mouse colons, transcriptomic and chromatin analyses, endogenous Apc-null adenoma model, IFNγ response assays\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal in vivo and molecular approaches in a single rigorous study\",\n      \"pmids\": [\"38418875\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"SOX17 regulates the differentiation and maintenance of the biliary/cholangiocyte phenotype; SOX17 knockdown in differentiated normal human cholangiocytes downregulates biliary markers and promotes Wnt-dependent proliferation; in CCA cells, SOX17 overexpression inhibits Wnt/β-catenin-dependent proliferation, migration, anchorage-independent growth, and restores primary cilium length; Wnt3a decreases SOX17 expression via a DNMT-dependent mechanism.\",\n      \"method\": \"Lentiviral SOX17 overexpression/knockdown, iPSC-to-cholangiocyte differentiation, xenograft model, gene expression profiling, DNA methylation profiling\",\n      \"journal\": \"Journal of hepatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal gain/loss-of-function with multiple mechanistic readouts and in vivo validation\",\n      \"pmids\": [\"28237397\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"SOX17 acts as a transcriptional repressor of NRF2; ChIP and promoter reporter analyses demonstrated direct SOX17 binding to the NRF2 promoter and suppression of its activity, providing a mechanism for chemoradiotherapy sensitization in esophageal squamous cell carcinoma.\",\n      \"method\": \"ChIP-qPCR, promoter luciferase reporter assay, SOX17 overexpression, xenograft model\",\n      \"journal\": \"Journal of biomedical science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 — direct promoter binding by ChIP plus reporter assay, single lab\",\n      \"pmids\": [\"36310172\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"SOX17 transcriptionally downregulates DNA repair and damage response genes (BRCA1, BRCA2, RAD51, KU80, DNAPK, p21, SIRT1, NFAT5, REV3L) in radio-resistant esophageal cancer cells, sensitizing them to chemoradiation; demonstrated by luciferase and ChIP-qPCR assays.\",\n      \"method\": \"Luciferase reporter assay, ChIP-qPCR, SOX17 overexpression, xenograft model, clonogenic survival assay\",\n      \"journal\": \"Journal of biomedical science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct transcriptional target identification by ChIP plus functional sensitization, single lab\",\n      \"pmids\": [\"30777052\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"SOX17 acts as a transcriptional suppressor of MRP3 (ABCC3) in cholangiocarcinoma cells; SOX17 expression prevents SOX2/SOX9-induced electrophoretic mobility shift of the ABCC3 promoter; this MRP3 downregulation reduces drug efflux and selectively sensitizes CCA cells to SN-38, 5-FU and mitoxantrone.\",\n      \"method\": \"TaqMan array resistome analysis, promoter reporter assay, EMSA, immunofluorescence, SOX17 adenoviral transduction, xenograft mouse model\",\n      \"journal\": \"Hepatology (Baltimore, Md.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — EMSA plus reporter plus in vivo rescue, multiple orthogonal methods\",\n      \"pmids\": [\"31863486\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"GATA3 or GATA2 (immediate BMP effectors) combined with SOX17 and TFAP2C are required to generate human PGCLCs; GATA3/GATA2 knockouts dose-dependently impair BMP-induced hPGCLC specification while remaining unaffected by SOX17, TFAP2C, or BLIMP1 knockouts, placing GATA3/2 upstream of SOX17 in the germ-cell specification transcription factor circuitry.\",\n      \"method\": \"TF overexpression, CRISPR knockout, hPGCLC specification assay, xenogeneic reconstituted ovary culture\",\n      \"journal\": \"Life science alliance\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — epistasis via CRISPR KO combined with reconstitution assay\",\n      \"pmids\": [\"33608411\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Sox17 deletion from endocardium precursor cells impairs endocardium proliferation and behavior, and in a non-cell-autonomous manner reduces cardiomyocyte proliferation, ventricular trabeculation and myocardium thickening, associated with downregulation of NOTCH signaling in the mutant.\",\n      \"method\": \"Mesoderm-specific Sox17 conditional deletion, cardiac phenotypic analysis, Notch target gene expression\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — conditional KO with defined Notch pathway readout, single lab\",\n      \"pmids\": [\"31420575\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Sox17 regulates insulin secretion in pancreatic β cells; Sox17 pancreas-specific deletion results in elevated islet proinsulin content, abnormal proinsulin trafficking, dilated secretory organelles, and susceptibility to hyperglycemia; Sox17 overexpression broadly regulates secretory network gene expression and can reverse insulin secretory defects in MODY4 animals.\",\n      \"method\": \"Pancreas-specific Sox17 conditional knockout, Ins2-rtTA overexpression, transcriptome analysis (24-hour SOX17 pulse), electron microscopy of organelles\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — conditional KO + inducible OE with cellular and transcriptomic readouts, single lab\",\n      \"pmids\": [\"25144761\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Sox17 regulates liver lipid metabolism and adaptation to fasting through modulation of PPARα-driven transcription; a missense mutation in the HMG domain of Sox17 impairs PPARα-dependent fatty acid oxidation gene induction during fasting; fenofibrate (PPARα agonist) partially rescues the fasting phenotype.\",\n      \"method\": \"Forward genetic screen, ENU mutagenesis, transcriptomic analysis, metabolic phenotyping, fenofibrate rescue in Sox17 mutant mice\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo HMG-domain missense mutant with transcriptomic and pharmacological rescue\",\n      \"pmids\": [\"25141153\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"The deubiquitinase UCHL1 interacts with Sox17 (identified by IP-mass spectrometry) and stabilizes the Sox17 protein; UCHL1 conditional knockout reduces Sox17 levels, impairs angiogenesis and blood-spinal cord barrier repair after spinal cord injury; rescue experiments confirm the UCHL1-Sox17 axis is required for endothelial regeneration.\",\n      \"method\": \"IP-mass spectrometry, UCHL1 conditional knockout mice, Sox17 knockdown/overexpression, rescue experiments, in vitro endothelial tube formation, in vivo SCI model\",\n      \"journal\": \"Cellular and molecular life sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — IP-MS identification of interaction plus conditional KO rescue, single lab\",\n      \"pmids\": [\"38478109\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"SOX17 overexpression promotes exosome-mediated autocrine release of miR-224-5p and miR-361-3p in pulmonary artery endothelial cells; these miRNAs are internalized by injured HPAECs and repress NR4A3 and PCSK9, improving endothelial function and attenuating pulmonary hypertension in SU5416/hypoxia mice.\",\n      \"method\": \"Exosome isolation and characterization, miRNA profiling, gain/loss-of-function in HPAECs and mice, luciferase target validation, in vivo SOX17 overexpression\",\n      \"journal\": \"Advanced science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — mechanistic exosome-miRNA pathway identified with in vivo model, single lab\",\n      \"pmids\": [\"36919784\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"SOX17 Sox17 promotes oligodendrocyte lineage survival under demyelinating conditions; Sox17 transgenic overexpression increases Gli2 protein levels in white matter, indicating Sox17 promotes oligodendrocyte generation through Hedgehog signaling, and prevents injury-induced TCF7L2/TCF4+ cell expansion and apoptosis by maintaining Gli2 and Bcl-2 expression.\",\n      \"method\": \"CNP-Sox17 transgenic mice, lysolecithin demyelination model, western blot, immunostaining\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — transgenic OE in demyelination model with Hedgehog pathway readout, single lab\",\n      \"pmids\": [\"23884956\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"SOX17 regulates fibroblast lineage conversion to endothelial cells and erythroblasts via intermediate CD34+ progenitors; endothelial conversion requires SOX17 upregulation, while SOX17 suppression directs cells toward erythroid fate; implanted cells form functional microvessels in NOD-SCID mice.\",\n      \"method\": \"Fibroblast reprogramming, CD34+ sorting, SOX17 overexpression/suppression, lineage-specific differentiation assays, mouse myocardial infarction model\",\n      \"journal\": \"Circulation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — gain/loss-of-function identifying SOX17 as a bifurcation switch, single lab\",\n      \"pmids\": [\"28381471\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Biliatresone causes a rapid decrease in glutathione and SOX17 levels in mouse cholangiocytes; GSH decrease is necessary and sufficient for biliatresone effects; Sox17 knockdown in cholangiocyte spheroids mimics biliatresone-induced disruption of apical polarity and monolayer integrity.\",\n      \"method\": \"3D cholangiocyte spheroid culture, neonatal bile duct explants, Sox17 siRNA knockdown, rhodamine efflux permeability assay\",\n      \"journal\": \"Hepatology (Baltimore, Md.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — knockdown phenocopying toxin in 3D culture plus explant model, single lab\",\n      \"pmids\": [\"27081925\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"In Xenopus, Sox17 acts as an immediate-early target of VegT in vegetal blastomeres: VegT activates Sox17α at the MBT independently of Nodal; thereafter, Sox17α prevents mesodermal gene expression (Xbra, MyoD) in response to Nodal signals while permitting endodermal gene expression, thereby establishing the endodermal domain.\",\n      \"method\": \"Inhibitor injection (VegT/Nodal MOs), animal cap explants, cycloheximide treatment, Nodal antagonist, gene expression analysis\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — epistasis experiments with multiple pathway components in Xenopus (ortholog)\",\n      \"pmids\": [\"11518513\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Oct4 switches binding from the Sox2 promoter to the Sox17 promoter upon BMP2-induced upregulation, turning off the pluripotency Oct4-Sox2 loop and activating Sox17-positive endodermal cells that produce cardiogenic paracrine signals (Wnt, BMP2).\",\n      \"method\": \"Oct4 overexpression and BMP2 treatment in human ESCs and iPSCs, ChIP (Oct4 on Sox17 promoter), promoter activity assay\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP evidence for Oct4 promoter switch plus functional differentiation assay, single lab\",\n      \"pmids\": [\"19736317\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"SOX17 promoter methylation silences its expression in HCC; restoration of SOX17 inhibits HepG2 colony formation and β-catenin/TCF-dependent transcription in a manner dependent on the HMG box; HCC with methylated SOX17 is associated with nuclear β-catenin accumulation.\",\n      \"method\": \"MSP, 5-aza-2'-deoxycytidine re-expression, luciferase reporter assay, colony formation assay, IHC\",\n      \"journal\": \"Epigenetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — reporter assay + epigenetic re-expression + HMG box requirement, single lab\",\n      \"pmids\": [\"20716954\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"In seminoma-like cells, SOX17 binds canonical (SOX2/OCT4), compressed (SOX17/OCT4), and non-composite SOX motifs; it regulates TFAP2C, PRDM1, and PRDM14 to maintain latent pluripotency and suppress somatic differentiation; SOX17 deletion reduces OCT4 protein and alkaline phosphatase activity, showing SOX17 functionally replaces SOX2 to maintain the pluripotency cluster in seminomas.\",\n      \"method\": \"ChIP-seq, CRISPR-mediated SOX17 deletion, alkaline phosphatase activity assay, Western blot\",\n      \"journal\": \"International journal of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP-seq plus CRISPR KO with functional readouts, single lab\",\n      \"pmids\": [\"31583686\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"SOX17 is an HMG-box transcription factor that: (1) bends DNA ~80° and forms alternative heterodimers with OCT4 on compressed vs. canonical Sox/Oct motifs to drive endoderm vs. pluripotency gene programs; (2) represses Wnt/β-catenin signaling by promoting proteasomal degradation of β-catenin and TCF, directly binding the β-catenin promoter, and physically interacting with TCF/LEF and co-factors such as MAML3; (3) functions downstream of canonical Wnt and upstream of Notch signaling to specify arterial identity and regulate vascular sprouting, BBB integrity, and pulmonary vascular homeostasis; (4) acts as a key specifier of human primordial germ cell fate, definitive endoderm identity, oligodendrocyte differentiation, and haemogenic endothelium; (5) is regulated post-translationally by deubiquitinase UCHL1-mediated stabilization, and transcriptionally by promoter methylation, HIF1α, and estrogen metabolites; and (6) controls downstream targets including Cyclin E1 (endothelial regeneration), VEGFR2, CDX2/HOXA (hematopoiesis), NRF2, MRP3, and secretory network genes (insulin trafficking), with loss-of-function linked to pulmonary arterial hypertension via HGF/c-Met and E2F1 signaling.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"SOX17 is an HMG-box transcription factor that specifies endodermal, vascular, hematopoietic, and germ cell fates by forming context-dependent transcriptional complexes and modulating Wnt/β-catenin signaling. Its HMG domain bends DNA ~80° and heterodimerizes with OCT4 on compressed Sox/Oct motifs to activate endodermal genes, whereas a canonical motif configuration supports pluripotency; single residue swaps at the OCT4 interface convert SOX17 into a reprogramming factor, demonstrating that the DNA-dependent dimer geometry dictates cell-fate outcome [PMID:19328208, PMID:21472822, PMID:23474895]. SOX17 represses Wnt/β-catenin transcriptional activity through multiple mechanisms—promoting GSK3β-independent proteasomal degradation of β-catenin and TCF/LEF, directly binding the β-catenin promoter, and co-occupying Wnt-responsive enhancers where it can either synergize with or antagonize β-catenin/TCF depending on the locus [PMID:17875931, PMID:29970906, PMID:32894225]. In endothelial cells, SOX17 operates downstream of Wnt and upstream of Notch signaling to specify arterial identity, regulate blood–brain barrier integrity, drive endothelial regeneration via HIF1α-induced Cyclin E1 activation, and maintain pulmonary vascular homeostasis—loss of endothelial SOX17 activates HGF/c-Met and E2F1 pathways that promote pulmonary arterial hypertension [PMID:24153254, PMID:31073164, PMID:30591003, PMID:36205124, PMID:37737027].\",\n  \"teleology\": [\n    {\n      \"year\": 2004,\n      \"claim\": \"Establishing that SOX17 functions as a sequence-specific transcriptional activator through its HMG box answered the basic question of how SOX17 engages endodermal target genes, using the Lama1 enhancer as a paradigm.\",\n      \"evidence\": \"EMSA, luciferase reporter, and mutational analysis in F9 parietal endoderm cells\",\n      \"pmids\": [\"15220343\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Limited to a single target gene enhancer\", \"Genome-wide binding landscape unknown at this stage\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Demonstrating that SOX17 controls both cell cycle exit and differentiation of oligodendrocyte progenitors revealed an unexpected non-endodermal role and showed SOX17 couples proliferation arrest to lineage progression.\",\n      \"evidence\": \"Reciprocal gain/loss-of-function in FACS-purified OPCs with MBP promoter reporter\",\n      \"pmids\": [\"16988043\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct transcriptional targets in OPCs beyond MBP not identified\", \"Mechanism linking SOX17 to cell cycle exit unresolved\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Revealing that SOX17 physically interacts with TCF/LEF and β-catenin and promotes their proteasomal degradation established SOX17 as a direct antagonist of canonical Wnt signaling through a GSK3β-independent mechanism.\",\n      \"evidence\": \"Co-IP, proteasome inhibitor rescue, luciferase reporter in SW480 colon carcinoma cells\",\n      \"pmids\": [\"17875931\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"E3 ubiquitin ligase mediating β-catenin/TCF degradation not identified\", \"Whether this degradation mechanism operates in non-cancer contexts unknown\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"The crystal structure of the SOX17 HMG domain on DNA showed that despite conserved minor-groove bending (~80°), an altered charge distribution at the co-factor interface predicts differential partner recruitment relative to SOX2, providing a structural basis for lineage-specific activity.\",\n      \"evidence\": \"X-ray crystallography at 2.7 Å with DNA-binding affinity measurements\",\n      \"pmids\": [\"19328208\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No co-crystal with OCT4 obtained\", \"Structural basis of compressed vs. canonical motif selectivity not resolved\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Xenopus studies and gastric cancer epigenetic analyses together established that SOX17 is an immediate-early endoderm specification factor (activated by VegT independently of Nodal) and that its promoter is silenced by DNA methylation in GI tumors, linking developmental function to tumor suppression.\",\n      \"evidence\": \"Xenopus animal cap epistasis with cycloheximide/Nodal antagonists; MSP/demethylation plus transgenic mice in gastric cancer\",\n      \"pmids\": [\"11518513\", \"19549530\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Methyltransferases responsible for SOX17 silencing not identified\", \"Whether Nodal-independent activation is conserved in mammals unclear\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Structure-guided swap of single residues at the OCT4 interface (SOX17EK) converted SOX17 into a pluripotency reprogramming factor, proving that the DNA-dependent Sox/Oct dimer configuration—not the overall protein—dictates cell-fate outcome between endoderm and pluripotency.\",\n      \"evidence\": \"Mutagenesis, somatic cell reprogramming assays, ESC overexpression\",\n      \"pmids\": [\"21472822\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream gene regulatory networks controlled by each dimer configuration not fully mapped\", \"Whether compressed motif preference is hardwired or chromatin-dependent unknown\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Ectopic SOX17 in adult HSCs conferred fetal-like self-renewal properties and eventually caused leukemia, establishing SOX17 as a master regulator of the fetal-to-adult HSC transition.\",\n      \"evidence\": \"Retroviral Sox17 overexpression in adult HSCs with serial bone marrow transplantation\",\n      \"pmids\": [\"21828271\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct transcriptional targets mediating fetal HSC identity not identified\", \"Mechanism of leukemogenic transformation unresolved\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Endothelial-specific Sox17 deletion and ChIP-seq studies established that SOX17 sits in a Wnt→SOX17→Notch epistatic hierarchy to specify arterial identity and regulate haemogenic endothelium, integrating its roles in vascular and hematopoietic development.\",\n      \"evidence\": \"Conditional EC knockout mice with Wnt/Notch epistasis; Sox17-GFP reporter in haemogenic endothelium; ChIP-seq identifying compressed Sox/Oct motifs at endodermal genes\",\n      \"pmids\": [\"24153254\", \"23604320\", \"23474895\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How SOX17 activates Notch ligand transcription mechanistically unclear\", \"Relative contributions of Wnt-dependent vs. Wnt-independent SOX17 activation in vivo not dissected\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Identification of SOX17 as the key transcription factor for human primordial germ cell specification—replacing the role of SOX2 in mouse—established a fundamental species-specific difference in germ cell biology.\",\n      \"evidence\": \"hPGCLC specification from hPSCs with siRNA/knockout, gain-of-function, transcriptome analysis\",\n      \"pmids\": [\"25543152\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct SOX17 targets in early hPGCs not comprehensively mapped\", \"Mechanism by which SOX17 supersedes SOX2 function in humans not fully elucidated\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Multiple 2014 studies clarified SOX17's downstream targets in distinct lineages: Cer1 in cardiac mesoderm, secretory network genes in pancreatic β cells, and VEGFR2 in tip cells, revealing that SOX17 controls tissue-specific gene programs rather than a single universal target set.\",\n      \"evidence\": \"ChIP/reporter for Cer1 in ESC cardiac differentiation; pancreas-specific KO with EM; EC-specific KO/OE retinal angiogenesis with Notch epistasis\",\n      \"pmids\": [\"24585688\", \"25144761\", \"24755984\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cofactors that confer tissue-specific target selectivity largely unknown\", \"Whether SOX17 directly binds VEGFR2 regulatory elements not confirmed by ChIP\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Demonstrating that SOX17 directly binds the β-catenin promoter to transcriptionally repress β-catenin expression added a second mechanism—transcriptional repression—to the previously known post-translational degradation route for Wnt pathway antagonism.\",\n      \"evidence\": \"ChIP-qPCR on β-catenin promoter, TOP/FOP-Flash reporter, colony formation in cervical cancer cells\",\n      \"pmids\": [\"29970906\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether both mechanisms (degradation + transcriptional repression) operate simultaneously in the same cell type not tested\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"The HIF1α→SOX17→Cyclin E1 axis was identified as the mechanism for endothelial regeneration after inflammatory injury, resolving how native endothelium self-repairs and placing SOX17 as a proliferation driver in the vascular context.\",\n      \"evidence\": \"Endothelial-specific Sox17 deletion/OE, genetic lineage tracing, ChIP, endotoxemia model\",\n      \"pmids\": [\"31073164\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether this regenerative pathway operates in chronic vascular injury models unknown\", \"Additional HIF1α-independent SOX17 activators not excluded\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"SOX17 was shown to maintain blood–brain barrier integrity; its loss increased brain microvascular permeability, and β-catenin stabilization rescued the defect, revealing that SOX17 positively reinforces Wnt/β-catenin signaling specifically in brain endothelium—contrasting with its Wnt-antagonist role in other contexts.\",\n      \"evidence\": \"Endothelial-specific Sox17 KO mice, RNA-seq, β-catenin destruction complex inhibitor rescue\",\n      \"pmids\": [\"30591003\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which SOX17 activates rather than represses Wnt pathway in brain EC not resolved\", \"Whether BBB defect is developmental or maintenance-related not fully distinguished\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Genome-wide co-occupancy of SOX17 and β-catenin on Wnt-responsive enhancers in Xenopus endoderm, with locus-dependent synergistic or antagonistic effects, resolved the paradox of SOX17 as both Wnt activator and repressor by showing it acts as a tissue-specific modifier of Wnt target selection.\",\n      \"evidence\": \"ChIP-seq, ATAC-seq, epistasis experiments, reporter assays in Xenopus gastrula\",\n      \"pmids\": [\"32894225\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Chromatin features or cofactors that determine synergy vs. antagonism at individual enhancers not identified\", \"Whether this locus-specific logic is conserved in mammalian endoderm unclear\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Placing GATA3/GATA2 upstream of SOX17 and identifying CDX2/HOXA as direct downstream targets in hemogenic endothelium completed the transcription factor hierarchy for human PGC and hematopoietic specification involving SOX17.\",\n      \"evidence\": \"CRISPR KO epistasis in hPGCLC assay; SOX17-KO/inducible hPSCs with ChIP for CDX2\",\n      \"pmids\": [\"33608411\", \"33596423\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full enhancer-level wiring connecting GATA→SOX17→CDX2 not mapped\", \"Whether SOX17 requirement is dose-dependent or switch-like not tested\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"SOX17 was found to physically interact with PAX8 and co-regulate angiogenic and cell-cycle genes in ovarian cancer, identifying a non-canonical partner outside the SOX/OCT paradigm.\",\n      \"evidence\": \"Reciprocal pulldown, Co-IP, ChIP-seq co-occupancy, siRNA, tube formation assay, xenograft\",\n      \"pmids\": [\"35380877\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of SOX17-PAX8 interaction unknown\", \"Whether this complex operates outside ovarian cancer cells not tested\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Endothelial Sox17 deficiency was linked to pulmonary arterial hypertension through de-repression of HGF/c-Met signaling, with pharmacological c-Met inhibition rescuing PAH, providing a therapeutic target downstream of SOX17 loss.\",\n      \"evidence\": \"EC-specific Sox17 deletion, transcriptomics, HGF/c-Met inhibitor rescue in hypoxia PAH model\",\n      \"pmids\": [\"36205124\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether SOX17 directly represses HGF transcription not demonstrated by ChIP\", \"Applicability to human PAH patient-derived cells not shown\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Common PAH risk variants were shown to reduce SOX17 expression via differential transcription factor binding (HOXA5, ROR-α) at an upstream enhancer, and E2F1 was identified as a key downstream effector of SOX17 loss in pulmonary hypertension, providing a genetic-to-mechanistic link for disease.\",\n      \"evidence\": \"EMSA, enhancer CRISPR KO, scRNA-seq, pharmacological E2F1 inhibition in Sox17-deficient mice\",\n      \"pmids\": [\"37066790\", \"37737027\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether enhancer variants fully account for PAH penetrance unclear\", \"Additional transcription factors binding the risk enhancer may exist\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"SOX17 was identified as a driver of immune evasion in colorectal cancer by suppressing IFNγ responsiveness and MHC-I expression through engagement of a fetal intestinal program, reframing SOX17 from a tumor suppressor to a context-dependent oncogenic factor.\",\n      \"evidence\": \"SOX17-null organoid transplantation, chromatin/transcriptomic analysis, CD8+ T cell infiltrate quantification\",\n      \"pmids\": [\"38418875\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether SOX17-driven immune evasion operates in other tumor types unknown\", \"Direct chromatin targets mediating IFNγ pathway suppression not fully resolved\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"UCHL1 was identified as a deubiquitinase that stabilizes SOX17 protein, establishing the first post-translational regulatory mechanism for SOX17 turnover.\",\n      \"evidence\": \"IP-mass spectrometry, UCHL1 conditional KO mice, rescue experiments in spinal cord injury model\",\n      \"pmids\": [\"38478109\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"E3 ligase that ubiquitinates SOX17 not identified\", \"Ubiquitination sites on SOX17 not mapped\", \"Whether UCHL1-SOX17 axis operates in endoderm or hematopoietic contexts untested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include: the structural basis of the SOX17–OCT4 complex on compressed DNA motifs; the cofactors and chromatin features determining locus-specific Wnt synergy vs. antagonism; the E3 ligase(s) targeting SOX17 for ubiquitin-dependent degradation; and whether SOX17's context-dependent tumor-suppressive vs. immune-evasive roles can be therapeutically dissected.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No SOX17–OCT4 co-crystal structure on compressed motif\", \"E3 ligase for SOX17 ubiquitination unknown\", \"Therapeutic window between endothelial protective and tumor immune-evasive functions not explored\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [1, 2, 3, 7, 13]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 7, 8, 9, 17, 29, 30]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 13, 17]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [1, 3, 7, 14, 22, 44]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": []},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 5, 12, 13, 17, 23]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [7, 8, 9, 29, 30]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [4, 5, 6, 16, 32, 41]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"OCT4\",\n      \"TCF/LEF\",\n      \"CTNNB1\",\n      \"PAX8\",\n      \"MAML3\",\n      \"UCHL1\",\n      \"HIF1A\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\nWait, I notice I accidentally included a stray GO entry in the pathway section. Let me fix the output:\n\n```json\n{\n  \"mechanistic_narrative\": \"SOX17 is an HMG-box transcription factor that specifies endodermal, vascular, hematopoietic, and germ cell fates by forming context-dependent transcriptional complexes and modulating Wnt/β-catenin signaling. Its HMG domain bends DNA ~80° and heterodimerizes with OCT4 on compressed Sox/Oct motifs to activate endodermal genes, whereas a canonical motif configuration supports pluripotency; single residue swaps at the OCT4 interface convert SOX17 into a reprogramming factor, demonstrating that the DNA-dependent dimer geometry dictates cell-fate outcome [PMID:19328208, PMID:21472822, PMID:23474895]. SOX17 represses Wnt/β-catenin transcriptional activity through multiple mechanisms—promoting GSK3β-independent proteasomal degradation of β-catenin and TCF/LEF, directly binding the β-catenin promoter, and co-occupying Wnt-responsive enhancers where it can either synergize with or antagonize β-catenin/TCF depending on the genomic locus [PMID:17875931, PMID:29970906, PMID:32894225]. In endothelial cells, SOX17 operates downstream of Wnt and upstream of Notch signaling to specify arterial identity, regulate blood–brain barrier integrity, drive endothelial regeneration via HIF1α-induced Cyclin E1 activation, and maintain pulmonary vascular homeostasis—loss of endothelial SOX17 activates HGF/c-Met and E2F1 pathways that promote pulmonary arterial hypertension [PMID:24153254, PMID:31073164, PMID:30591003, PMID:36205124, PMID:37737027].\",\n  \"teleology\": [\n    {\n      \"year\": 2004,\n      \"claim\": \"Establishing that SOX17 functions as a sequence-specific transcriptional activator through its HMG box answered the basic question of how SOX17 engages endodermal target genes, using the Lama1 enhancer as a paradigm.\",\n      \"evidence\": \"EMSA, luciferase reporter, and mutational analysis in F9 parietal endoderm cells\",\n      \"pmids\": [\"15220343\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Limited to a single target gene enhancer\", \"Genome-wide binding landscape unknown at this stage\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Demonstrating that SOX17 controls both cell cycle exit and differentiation of oligodendrocyte progenitors revealed an unexpected non-endodermal role and showed SOX17 couples proliferation arrest to lineage progression.\",\n      \"evidence\": \"Reciprocal gain/loss-of-function in FACS-purified OPCs with MBP promoter reporter\",\n      \"pmids\": [\"16988043\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct transcriptional targets in OPCs beyond MBP not identified\", \"Mechanism linking SOX17 to cell cycle exit unresolved\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Revealing that SOX17 physically interacts with TCF/LEF and β-catenin and promotes their proteasomal degradation established SOX17 as a direct antagonist of canonical Wnt signaling through a GSK3β-independent mechanism.\",\n      \"evidence\": \"Co-IP, proteasome inhibitor rescue, luciferase reporter in SW480 colon carcinoma cells\",\n      \"pmids\": [\"17875931\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"E3 ubiquitin ligase mediating β-catenin/TCF degradation not identified\", \"Whether this degradation mechanism operates in non-cancer contexts unknown\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"The crystal structure of the SOX17 HMG domain on DNA showed that despite conserved minor-groove bending (~80°), an altered charge distribution at the co-factor interface predicts differential partner recruitment relative to SOX2, providing a structural basis for lineage-specific activity.\",\n      \"evidence\": \"X-ray crystallography at 2.7 Å with DNA-binding affinity measurements\",\n      \"pmids\": [\"19328208\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No co-crystal with OCT4 obtained\", \"Structural basis of compressed vs. canonical motif selectivity not resolved\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Xenopus studies and gastric cancer epigenetic analyses together established that SOX17 is an immediate-early endoderm specification factor (activated by VegT independently of Nodal) and that its promoter is silenced by DNA methylation in GI tumors, linking developmental function to tumor suppression.\",\n      \"evidence\": \"Xenopus animal cap epistasis with cycloheximide/Nodal antagonists; MSP/demethylation plus transgenic mice in gastric cancer\",\n      \"pmids\": [\"11518513\", \"19549530\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Methyltransferases responsible for SOX17 silencing not identified\", \"Whether Nodal-independent activation is conserved in mammals unclear\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Structure-guided swap of single residues at the OCT4 interface (SOX17EK) converted SOX17 into a pluripotency reprogramming factor, proving that the DNA-dependent Sox/Oct dimer configuration—not the overall protein—dictates cell-fate outcome between endoderm and pluripotency.\",\n      \"evidence\": \"Mutagenesis, somatic cell reprogramming assays, ESC overexpression\",\n      \"pmids\": [\"21472822\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream gene regulatory networks controlled by each dimer configuration not fully mapped\", \"Whether compressed motif preference is hardwired or chromatin-dependent unknown\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Ectopic SOX17 in adult HSCs conferred fetal-like self-renewal properties and eventually caused leukemia, establishing SOX17 as a master regulator of the fetal-to-adult HSC transition.\",\n      \"evidence\": \"Retroviral Sox17 overexpression in adult HSCs with serial bone marrow transplantation\",\n      \"pmids\": [\"21828271\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct transcriptional targets mediating fetal HSC identity not identified\", \"Mechanism of leukemogenic transformation unresolved\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Endothelial-specific Sox17 deletion and ChIP-seq studies established that SOX17 sits in a Wnt→SOX17→Notch epistatic hierarchy to specify arterial identity and regulate haemogenic endothelium, integrating its roles in vascular and hematopoietic development.\",\n      \"evidence\": \"Conditional EC knockout mice with Wnt/Notch epistasis; Sox17-GFP reporter in haemogenic endothelium; ChIP-seq identifying compressed Sox/Oct motifs at endodermal genes\",\n      \"pmids\": [\"24153254\", \"23604320\", \"23474895\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How SOX17 activates Notch ligand transcription mechanistically unclear\", \"Relative contributions of Wnt-dependent vs. Wnt-independent SOX17 activation in vivo not dissected\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Identification of SOX17 as the key transcription factor for human primordial germ cell specification—replacing the role of SOX2 in mouse—established a fundamental species-specific difference in germ cell biology.\",\n      \"evidence\": \"hPGCLC specification from hPSCs with siRNA/knockout, gain-of-function, transcriptome analysis\",\n      \"pmids\": [\"25543152\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct SOX17 targets in early hPGCs not comprehensively mapped\", \"Mechanism by which SOX17 supersedes SOX2 function in humans not fully elucidated\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Multiple 2014 studies clarified SOX17's downstream targets in distinct lineages: Cer1 in cardiac mesoderm, secretory network genes in pancreatic β cells, and VEGFR2 in tip cells, revealing that SOX17 controls tissue-specific gene programs rather than a single universal target set.\",\n      \"evidence\": \"ChIP/reporter for Cer1 in ESC cardiac differentiation; pancreas-specific KO with EM; EC-specific KO/OE retinal angiogenesis with Notch epistasis\",\n      \"pmids\": [\"24585688\", \"25144761\", \"24755984\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cofactors that confer tissue-specific target selectivity largely unknown\", \"Whether SOX17 directly binds VEGFR2 regulatory elements not confirmed by ChIP\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Demonstrating that SOX17 directly binds the β-catenin promoter to transcriptionally repress β-catenin expression added a second mechanism—transcriptional repression—to the previously known post-translational degradation route for Wnt pathway antagonism.\",\n      \"evidence\": \"ChIP-qPCR on β-catenin promoter, TOP/FOP-Flash reporter, colony formation in cervical cancer cells\",\n      \"pmids\": [\"29970906\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether both mechanisms (degradation and transcriptional repression) operate simultaneously in the same cell type not tested\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"The HIF1α→SOX17→Cyclin E1 axis was identified as the mechanism for endothelial regeneration after inflammatory injury, resolving how native endothelium self-repairs and placing SOX17 as a proliferation driver in the vascular context.\",\n      \"evidence\": \"Endothelial-specific Sox17 deletion/OE, genetic lineage tracing, ChIP, endotoxemia model\",\n      \"pmids\": [\"31073164\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether this regenerative pathway operates in chronic vascular injury models unknown\", \"Additional HIF1α-independent SOX17 activators not excluded\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"SOX17 was shown to maintain blood–brain barrier integrity; its loss increased brain microvascular permeability, and β-catenin stabilization rescued the defect, revealing that SOX17 positively reinforces Wnt/β-catenin signaling specifically in brain endothelium—contrasting with its Wnt-antagonist role in other contexts.\",\n      \"evidence\": \"Endothelial-specific Sox17 KO mice, RNA-seq, β-catenin destruction complex inhibitor rescue\",\n      \"pmids\": [\"30591003\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which SOX17 activates rather than represses Wnt pathway in brain EC not resolved\", \"Whether BBB defect is developmental or maintenance-related not fully distinguished\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Genome-wide co-occupancy of SOX17 and β-catenin on Wnt-responsive enhancers in Xenopus endoderm, with locus-dependent synergistic or antagonistic effects, resolved the paradox of SOX17 as both Wnt activator and repressor by showing it acts as a tissue-specific modifier of Wnt target selection.\",\n      \"evidence\": \"ChIP-seq, ATAC-seq, epistasis experiments, reporter assays in Xenopus gastrula\",\n      \"pmids\": [\"32894225\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Chromatin features or cofactors that determine synergy vs. antagonism at individual enhancers not identified\", \"Whether this locus-specific logic is conserved in mammalian endoderm unclear\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Placing GATA3/GATA2 upstream of SOX17 and identifying CDX2/HOXA as direct downstream targets in hemogenic endothelium completed the transcription factor hierarchy for human PGC and hematopoietic specification involving SOX17.\",\n      \"evidence\": \"CRISPR KO epistasis in hPGCLC assay; SOX17-KO/inducible hPSCs with ChIP for CDX2\",\n      \"pmids\": [\"33608411\", \"33596423\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full enhancer-level wiring connecting GATA→SOX17→CDX2 not mapped\", \"Whether SOX17 requirement is dose-dependent or switch-like not tested\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"SOX17 was found to physically interact with PAX8 and co-regulate angiogenic and cell-cycle genes in ovarian cancer, identifying a non-canonical partner outside the SOX/OCT paradigm.\",\n      \"evidence\": \"Reciprocal pulldown, Co-IP, ChIP-seq co-occupancy, siRNA, tube formation assay, xenograft\",\n      \"pmids\": [\"35380877\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of SOX17-PAX8 interaction unknown\", \"Whether this complex operates outside ovarian cancer cells not tested\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Endothelial Sox17 deficiency was linked to pulmonary arterial hypertension through de-repression of HGF/c-Met signaling, with pharmacological c-Met inhibition rescuing PAH, providing a therapeutic target downstream of SOX17 loss.\",\n      \"evidence\": \"EC-specific Sox17 deletion, transcriptomics, HGF/c-Met inhibitor rescue in hypoxia PAH model\",\n      \"pmids\": [\"36205124\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether SOX17 directly represses HGF transcription not demonstrated by ChIP\", \"Applicability to human PAH patient-derived cells not shown\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Common PAH risk variants were shown to reduce SOX17 expression via differential transcription factor binding (HOXA5, ROR-α) at an upstream enhancer, and E2F1 was identified as a key downstream effector of SOX17 loss in pulmonary hypertension, providing a genetic-to-mechanistic link for disease.\",\n      \"evidence\": \"EMSA, enhancer CRISPR KO, scRNA-seq, pharmacological E2F1 inhibition in Sox17-deficient mice\",\n      \"pmids\": [\"37066790\", \"37737027\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether enhancer variants fully account for PAH penetrance unclear\", \"Additional transcription factors binding the risk enhancer may exist\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"SOX17 was identified as a driver of immune evasion in colorectal cancer by suppressing IFNγ responsiveness and MHC-I expression through engagement of a fetal intestinal program, reframing SOX17 from a tumor suppressor to a context-dependent oncogenic factor.\",\n      \"evidence\": \"SOX17-null organoid transplantation, chromatin/transcriptomic analysis, CD8+ T cell infiltrate quantification\",\n      \"pmids\": [\"38418875\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether SOX17-driven immune evasion operates in other tumor types unknown\", \"Direct chromatin targets mediating IFNγ pathway suppression not fully resolved\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"UCHL1 was identified as a deubiquitinase that stabilizes SOX17 protein, establishing the first post-translational regulatory mechanism for SOX17 turnover.\",\n      \"evidence\": \"IP-mass spectrometry, UCHL1 conditional KO mice, rescue experiments in spinal cord injury model\",\n      \"pmids\": [\"38478109\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"E3 ligase that ubiquitinates SOX17 not identified\", \"Ubiquitination sites on SOX17 not mapped\", \"Whether UCHL1-SOX17 axis operates in endoderm or hematopoietic contexts untested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include: the structural basis of the SOX17–OCT4 complex on compressed DNA motifs; the cofactors and chromatin features determining locus-specific Wnt synergy vs. antagonism; the E3 ligase(s) targeting SOX17 for ubiquitin-dependent degradation; and whether SOX17's context-dependent tumor-suppressive vs. immune-evasive roles can be therapeutically dissected.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No SOX17–OCT4 co-crystal structure on compressed motif\", \"E3 ligase for SOX17 ubiquitination unknown\", \"Therapeutic window between endothelial protective and tumor immune-evasive functions not explored\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [1, 2, 3, 7, 13]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 7, 8, 9, 17, 29, 30]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [1, 7, 14, 22]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 5, 12, 13, 17, 23]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [7, 8, 9, 29, 30]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [4, 5, 6, 16, 32, 41]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"POU5F1\",\n      \"CTNNB1\",\n      \"TCF7L2\",\n      \"PAX8\",\n      \"MAML3\",\n      \"UCHL1\",\n      \"HIF1A\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}